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CHAPTER ONE 
GENERAL INTRODUCTION 
Dissertation Organization 
The following dissertation is organized into seven chapters. Chapter One is a review of 
the literature covering immunity in neonatal animals. Chapters Two through Six are a 
summary of research conducted to examine the effects of administration of exogenous 
immunoglobulin in neonatal animals. General conclusions from the experiments are in 
Chapter Seven. 
Neonatal Immunity: A Review 
Introduction 
The transition from fetal to neonatal life is a dramatic event in the life of any animal. Not 
only is the process of parturition itself demanding, but the fetus must also adapt from a state 
of maternal reliance to a state of complete independence. There are a number of metabolic 
and physiologic changes that must occur as the fetus adjusts to life outside the uterus, and the 
immune system is just one of the systems affected. Prior to parturition, the fetus is sheltered 
from most antigenic stimuli and is primarily protected by the maternal immune system. After 
birth, the immune system of the neonate must fend off antigenic challenges unassisted. This 
review focuses on the developing immune system of neonates, with emphasis on domestic 
farm animals. 
Fetal Immunity 
The fetal immune system is often incorrectly assumed to be unable to respond to antigen. 
Fetal calves (age 195-253 d) are able to mount both cell-mediated and humoral immune 
responses that are similar to adult cattle in response to tetanus toxoid injection (Tierney and 
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Simpson-Morgan, 1997). Immunoglobulin M and G can also be detected in the serum of 50 d 
old pig fetuses after intrauterine injection of antigen (Tlaskalova-Hogenova et al., 1994). The 
typical age at which lymphoid tissue appears in cattle is in Table 1.1 
Table 1.1. Lymphoid tissue development in the fetal calf (Schultz et al., 1971). 
Tissue Time of appearance (d) 
Thymus 42 
Blood lymphocytes 45 
Spleen 55 
IgM containing cells 59 
Peripheral lymph nodes 60 
Mesenteric lymph nodes 100 
Serum IgM 130 
Blood granulocytes 130 
IgG containing cells 145 
Serum IgG 145 
(bacterially infected fetus) 
GI tract lymphoid tissue 175 
The majority of T-cells in fetal lambs are CD5+ and the percentage of y§ T-cells 
increases 15-38% during the last 20-30 d of fetal life. Overall, the ratio of yô T-cells to a(3 T-
cells increases with fetal development (Washington et al., 1992). 
In humans, splenic cells are capable of synthesizing immunoglobulin M and G after 19 
weeks of gestation, and from 20 weeks of gestation onward, IgM can be detected in the 
serum of human fetuses (van Furth et al., 1965). However, synthesis of IgA or IgD is not 
detected up to 30 weeks of gestation, and no immunoglobulin synthesis is detected in the 
fetal thymus (van Furth et al., 1965). Immunoglobulin A secreting cells are also not found in 
cattle fetuses (Schultz et al., 1971). 
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Neonatal Immunity 
The human placenta is permeable to and favors fetal uptake of IgG (Dancis et al., 1961; 
Freda, 1962; Gitlin et al., 1964; Hobbs and Davis, 1967). Newborn babies have 
concentrations of serum IgG at approximately 89% of adult values, concentrations of serum 
IgM at 11% of adult values, and concentrations of serum IgA at only 1% of adult values. In 
contrast to humans, calves, piglets, lambs, and foals are essentially agammaglobulinemic at 
birth, although a small percentage may have negligible amounts of circulating serum IgGi, 
IgG2, IgM, and IgA. In these domestic farm animals, passive immunity is provided through 
colostrum (Smith and Holm, 1948; Klaus et al., 1969; Porter, 1969; McGuire and Crawford, 
1973; Jeffcott, 1974a; Husband and Lascelles, 1975; Stott et al., 1979c; Edwards et al., 1982; 
Lavoie et al., 1989; Sheoran et al., 2000). 
Bovine colostrum contains high concentrations of IgG, which decrease steadily after the 
first milking, with only 78% of the initial IgG concentration present at 12 h, and 48% of the 
initial IgG concentration present at 24 h (Oyeniyi and Hunter, 1978; Le vieux and Oilier, 
1999). In species lacking significant placental IgG transfer, colostral IgG is absorbed in the 
small intestine by two main mechanisms: selective (receptor-mediated), or non-selective 
antibody transfer. 
Selective Intestinal Transfer of IgG 
Neonatal rats utilize selective (receptor-mediated) IgG transfer in the intestine. The small 
intestine of one-day-old rats absorbs proteins non-specifically. However, by 3 d of age, IgG 
absorption is slightly increased compared to albumin and by 7 d of age, the small intestine 
absorbs IgG 20 times more selectively, with little to no absorption of albumin. At 21 d of 
age, no proteins are absorbed intact into the circulation (Bangham and Terry, 1957; Jordan 
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and Morgan, 1968; Jones, 1974). Expression of IgG binding protein also supports this trend, 
with increased expression in the small intestine from 0-21 d of age, and very low expression 
by 30 d of age (Jakoi et al., 1985). 
The large molecular weight molecule polyvinyl pyrrolidone (PVP; MW 160,000) also 
exhibits a similar absorption pattern to IgG. More than 50% of ingested PVP can be 
recovered from intestinal cells of rats younger than 18 d. Between 18-20 d the amount of 
PVP uptake declines progressively, with less than 5% absorbed after 20 d. This suggests that 
termination of antibody uptake in rats may be related to the loss of the ability to absorb high 
molecular weight molecules (Clarke and Hardy, 1969). However, PVP was detected in 
vacuoles of the distal intestine in this study, which exhibit non-selective protein absorption. 
This is in contrast to proximal cells, which selectively transport antibodies (Mackenzie, 1972; 
Rodewald, 1973; Jones, 1976; Mackenzie et al., 1983a; Mackenzie et al., 1983b). 
Antibodies from colostrum adhere to localized areas at the base of the microvilli in the 
proximal portion of the rat small intestine where they are selected to enter the cell; they are 
absorbed by pinocytosis into tubular vesicles. Antibodies are then transferred to spherical 
membrane coated vesicles and transferred to the lateral cell membrane where the contents are 
expelled into the lateral extracellular space (Rodewald, 1970; Rodewald, 1973). The IgG 
selection process can also be saturated, as IgG molecules compete for binding sites (Jones 
and Waldmann, 1972). After 22 d of age, proximal rat intestinal cells lose the ability to 
selectively absorb antibodies as described above. Material that enters cells is degraded 
instead of transported (Rodewald, 1973). 
The IgG binding protein from the proximal portion of rat small intestine preferentially 
binds IgGi. Preferential order of affinity is IgG^>IgG^b>IgG^a>IgG^ (Jakoi et al., 1985). 
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Optimal binding occurs at a pH of 6.0, with reduced affinity at higher and lower pH 
(Rodewald, 1976; Mackenzie et al., 1983b; Jakoi et al., 1985). Luminal pH recordings in 
different segments of intestine in 9-18 d old rats are: stomach, 5.1; duodenum, 6.2; jejunum, 
6.3; ileum, 6.9; supporting optimal IgG binding in the duodenum (Rodewald, 1976). 
The rat intestine also exhibits some preferences for species-specific IgG. 
Immunoglobulin G is transported intact across the intestine in neonatal rats with homologous 
antibody, as well as rabbit, primate, and human antibody being transferred preferentially over 
heterologous antibody, such as bovine or sheep; however, all IgG types are bound 
specifically over other proteins (Bangham and Terry, 1957; Bamford, 1966; Jordan and 
Morgan, 1968; Jones, 1972; Mackenzie, 1972; Jones, 1974; Mackenzie et al., 1983a; 
Mackenzie et al., 1983b). Also, neonatal rat intestine selectively absorbs sheep IgG% in 
preference to sheep IgGi (Mackenzie, 1972). 
Non-selective Intestinal Transfer of IgG 
In contrast to rats, neonatal domestic farm animals utilize non-selective intestinal 
transport of IgG molecules. Immunoglobulins G, M, and A are all absorbed non-selectively 
by neonatal calves in amounts relating to the proportion of the molecules in the colostrum 
consumed (Bangham et al., 1958; Klaus et al., 1969; Brandon and Lascelles, 1971; Stott et 
al., 1979b; Besser et al., 1985). In contrast, IgG is preferentially absorbed (compared to IgM 
and IgA) from colostrum in foals and piglets, and serum IgG concentrations reflect colostral 
IgG concentration (McGuire and Crawford, 1973; Butler et al., 1981; Morris et al., 1985). 
The piglet small intestine transports IgG and albumin with equal efficiency when these 
proteins are given separately; however, IgG transport efficiency is increased when given in 
combination with increasing amounts of another macromolecule such as albumin or PVP 
(Leary and Lecce, 1979). Also in piglets, IgA and IgM from colostrum are found adsorbed to 
the enterocyte apical surface; however, only faint amounts are detected in cells (Butler et al., 
1981). 
Unidentified factors in colostrum increase the rate of globulin absorption in neonatal 
calves. However, these factors are only effective prior to intestinal closure (Balfour and 
Comline, 1962). Colostrum also enhances PVP absorption from the neonatal foal intestine by 
10% (Jeffcot, 1974b). 
Concentrations of IgGi, IgG%, IgA, and IgM in the serum of calves are strongly correlated 
to the length of time between birth and suckling (Edwards et al., 1982). The highest rate of 
IgG absorption occurs during the first four hours after feeding, and absorption rate decreases 
with increasing age (Kruse, 1970; Stott et al., 1979b; Matte et al., 1982). Fifty percent of 
calves fed at 24 h of age are unable to absorb IgG, as are 23% of calves fed at 20 h and 10% 
of calves fed at 16 h (Stott et al., 1979a). In colostrum-fed calves, concentrations of serum 
gamma globulin increase steadily until approximately 16 h of age, at which time levels 
plateau (Patt et al., 1972). 
Similar to the calf, the small intestine of neonatal foals demonstrates maximum uptake of 
PVP soon after birth, with peak concentrations attained 6 h after administration. There is a 
progressive reduction in uptake to less than 1% of the dose entering the circulation at 20 h of 
age; PVP uptake is 22% of the total dose fed to foals at 3 h compared to 0.9% for foals fed at 
20 h (Jeffcott, 1974b). 
Mean time to gut closure in calves occurs approximately 26 h after birth for IgG, IgA, 
and IgM, and the amount of colostrum fed does not affect time to closure (Stott et al., 1979a). 
Calves older than 48 h of age do not show increases in serum immunoglobulin after infusion 
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of colostrum into the small intestine (Smith and Erwin, 1959). Age of first feeding can 
influence closure time in a linear fashion, with earlier feeding resulting in earlier closure. Gut 
closure to IgG absorption occurs at 21 h if calves are fed at birth and 33 h if feeding is 
delayed until 24 h. However, when colostrum feeding is delayed, the total absorptive period 
is decreased (21 h if fed at birth compared to 9 h if fed at 24 h) and maximum serum IgG 
concentrations are lower (Stott et al., 1979a; Stott et al., 1979c). 
Gut closure in domestic farm animals appears to be related to energy (glucose) 
availability and maturation of the intestine. The small intestine of fetal lambs absorbs up to 
20% of IgG infused for sustained periods of time, with no evidence of closure (Smeaton and 
Simpson-Morgan, 1985). Fetal lambs also have very low circulating glucose levels 
(Alexander et al., 1955; Comline and Silver, 1970). The ability of intestinal enterocytes to 
transport macromolecules, such as albumin and egg white, ceases between 24 -36 h 
postnatally in piglets; however, piglets fasted from birth until 60 h of age retain this transport 
ability (Leary and Lecce, 1978). Hypoxic calves (pOz ~ 26 mm Hg) do not exhibit gut 
closure until 42-48 h of age, whereas normoxic calves exhibit closure by 24 h of age (Tyler 
and Ramsey, 1991a). Hypoxia prolongs the time to gut closure by affecting postnatal 
increases in glucose; peak concentrations of glucose are reached at 42 h instead of 24 h as 
observed in control calves (Tyler and Ramsey, 1991b). 
Intestinal cell maturity and turnover rate also influences gut closure. Fetal lamb small 
intestinal crypt cells undergo mitosis at a slower rate than neonatal crypt cells, and therefore 
cell turnover is decreased (Smeaton and Simpson-Morgan, 1985). Epithelial cell migration is 
more rapid in one-day-old compared to 3-week old lambs, and is more rapid in the proximal 
compared to the distal small intestine (Moon and Joel, 1975). Cells migrate from the crypts 
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to approximately half way up the villous in 48 h in both one-day-old lambs and calves, and 
reach the tips of the villi in approximately 72 h (Moon and Joel, 1975; Smeaton and 
Simpson-Morgan, 1985). 
Prior to colostrum ingestion in newborn lambs, small intestinal epithelial cells stain 
poorly with basally located nuclei. The nuclei are displaced apically by large protein-filled 
vacuoles after colostrum ingestion. Cells filled with large vacuoles are visible along the villi 
the first day after birth, are only along the upper portion by the second day after birth, and are 
absent by the third day after birth (Smeaton and Simpson-Morgan, 1985). 
The ability of enterocytes from the small intestine of the neonatal piglet to take up 
macromolecules ceases (closure) in a sequential pattern from proximal to distal. 
Transposition of distal intestinal segments proximally does not affect macromolecule 
internalization. Thus, cellular differentiation with regard to macromolecule uptake occurs 
prior to birth, and flow of digesta does not influence time of closure (Leary and Lecce, 1976). 
Globulins are absorbed unchanged from the intestine of neonatal calves, and enter the 
lymphatic system 60-120 min after absorption. Globulins do not enter the portal circulation; 
instead, they enter peripheral blood from the lymphatic system (Comline et al., 1951; Balfour 
and Comline, 1961). Once in the circulation, distribution of IgG into the intravascular and 
extravascular space in newborn foals is 1:1, respectively, with equilibrium being reached in 
approximately 51 h (Reilly and Macdougall, 1973). 
Immunoglobulin G can also be secreted from the circulation back into the intestinal 
lumen through Fc receptors (FcR) located in the duodenal crypt cells (Besser et al., 1988; 
Mayer et al., 2002). Antibodies from circulation that appear in the intestinal tract can prevent 
infection and diarrhea in calves (Besser et al., 1988). 
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Factors Affecting IgG Absorption 
The proximal neonatal piglet small intestine transports more IgG into blood than does the 
distal small intestine; however, enterocytes from both segments internalize similar amounts 
of IgG. It appears that there is a difference between the ability of the enterocytes of the two 
segments to transport macromolecules from within the enterocyte into the blood (Leary and 
Lecce, 1979). 
As observed with rats, the absorptive process in the calf intestine appears to be saturable. 
Feeding 0.5 or 1 L of colostrum to calves for the first feeding does not saturate the absorptive 
ability of the gut, since a second feeding at 12 h increases absorption rates. However, feeding 
2 L for the first feeding does saturate the absorptive ability of the intestine as no increase is 
observed after feeding at 12 h (Stott et al., 1979b). 
The rate of IgG absorption increases as amount of colostrum fed increases (Stott et al., 
1979b; Stott et al., 1979d; Stott an Fellah, 1983). Calves fed larger amounts of colostrum (up 
to 2 L) at the initial feeding attain higher serum IgG concentrations. However, as age 
increases, response to initial feeding decreases (Stott et al., 1979c). Method of feeding also 
appears to have some influence on IgG absorption. Calves that suckle have higher rates of 
IgG absorption for the first 12 h after birth and attain higher total serum IgG concentrations 
compared to calves that are bottle fed a similar amount colostrum (Stott et al., 1979d). 
Apparent efficiency of absorption (AEA) of IgGi and IgM in calves decreases with 
increasing mass of the antibody in colostrum (Besser et al., 1985). When the mass of IgG, 
IgA, or IgM is held constant, greater amounts are absorbed when the concentration in the 
colostrum is higher - for example 1 L of colostrum containing 100 mg IgG/ml has is 
absorbed with greater efficiency than 2 L of colostrum containing 50 mg IgG/ml. However, 
when IgG concentration in colostrum is low (10-20 mg IgG/ml) there is no difference in 
absorption between feeding 1 L of colostrum containing 20 mg IgG/ml vs. 2 L of colostrum 
containing 10 mg IgG/ml (Stott and Fellah, 1983). 
The AEA of IgG in calves fed colostrum ranges from 23-32% (Morin et al, 1997; Drewry 
et al., 1999). Efficiency of absorption of IgM is almost 100%. The apparently lower 
absorptive efficiency for IgG is most likely due to loss of the molecule into the interstitial 
space (Husband et al., 1972). Efficiency of IgG and IgA absorption in calves does not appear 
to be influenced by amount of IgG or IgA fed or the concentration in colostrum (Kruse, 
1970; Stott and Menefee, 1978; Morin et al, 1997). Calves fed 3.8 L of colostrum in one 
feeding or divided into two feedings given 10-12 h apart attained similar total serum IgG 
concentrations and had a similar apparent efficiency of absorption (Hopkins and Quigley et 
al., 1997). Morin et al. (1997) also reported no difference in IgGi concentration in calves fed 
2 L three times (0 h, 6 h, and 12 h) and calves fed 4 L at birth and 2 L at 12 h. 
Although AEA does not change, the amount of IgG and IgA absorbed by calves by 12 h 
of age increases positively with the concentration fed (Stott and Fellah, 1983). 
Immunoglobulin M absorption appears to be slightly different than IgG or IgA, in that as 
amount of IgM in colostrum increases, serum IgM concentration increases at a decreasing 
rate (Stott and Menefee, 1978; Stott and Fellah, 1983). 
There are a variety of factors that have been suggested to influence colostral absorption 
of IgG, including the presence of microorganisms, colostral acidity, and presence of steroids. 
The addition of live microorganisms to the small intestine prior to colostrum ingestion 
decreased IgG absorption in neonatal calves (James and Polan, 1978; James et al., 1981). 
Also, addition of potassium isobutyrate to colostrum decreased absorption efficiency of IgG 
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to 25%, compared to 36% for unaltered colostrum (Baumwart et al., 1977). In contrast, the 
addition of whey protein concentrate or casein to maternal colostrum had no effect on IgG 
absorption by neonatal calves (Davenport et al., 2000). Colostral IgGi absorption was also 
not affected by treatment of calves with alkalinizing agents (Ayers and Besser, 1992). Low 
serum corticosteroid concentration is associated with decreased IgG uptake in neonatal 
calves; normal or increased corticosteroid concentrations has no effect on IgG uptake 
(Johnston and Oxender, 1979; James et al., 1981). Elevated levels of serum Cortisol also did 
not affect IgG uptake in foals (Carrick et al., 1987). Hypercapnia as determined at 1 h after 
birth did not affect AEA of colostrum or plasma IgG concentration at 25 h after birth 
(Drewry et al., 1999). Added histamine in gamma globulin preparations also did not affect 
gamma globulin concentrations in the serum of young calves (Patt et al., 1972). 
Endogenous IgG Production 
The half-life for IgG2 in the newborn infant is 16 days (Gitlin et al., 1964), and serum 
IgG levels in newborns decrease rapidly to approximately 37% of adult values by three 
months of age, and then increase rapidly to two years of age. After this time, serum IgG 
levels steadily increase until approximately 10 years of age, the time at which adult levels are 
attained (Stiehm and Fudenberg, 1966). There is no difference between term and preterm 
infants in the number of IgG and IgA secreting cells after birth, however, premature infants 
have lower numbers of IgM secreting cells after birth compared to term infants (Stoll et al., 
1993). 
The concentrations of IgGi, IgG2, IgM, and IgA in colostrum deprived calves begin to 
increase within a few days after birth, reaching levels comparable to colostrum fed calves for 
IgG2, IgM, and IgA by 16 - 32 d of age (Husband and Lascelles, 1975; Crowley et al., 1994). 
Concentrations of IgGi and IgG2 are reported to increase three-fold during the first eight days 
of life in colostrum deprived calves (Husband and Lascelles, 1975). In contrast, serum IgG 
concentrations are undetectable in colostrum-deprived foals until after 7 d of age, and 
concentrations remain negligible until two weeks of age. After this time, serum IgG 
concentrations rapidly begin to increase (Jeffcott, 1974a; Holmes and Lunn, 1991). 
A transitional period exists when passive immunity is waning and active immunity is 
developing from two weeks to four months of age in foals. Passively transferred equine IgG 
has a serum half-life of 23-39 d in newborn foals (Reilly and MacDougall, 1973; Jeffcott, 
1974a; Lavoie et al., 1989; Wilson et al., 2001). The half-life for maternally derived 
influenza antibodies is estimated at 27-39 d depending on the influenza strain and the IgG 
isotype (Van Maanen et al., 1992; Wilson et al, 2001). Smith and Holm (1948) estimated the 
half-life for passively acquired IgG in calves at 16-50 d and also reported that half-life 
depends on the specific antibody. Production of endogenous IgG rapidly increases when 
concentrations of passively attained IgG become low (Jeffcott, 1974a). More specifically, 
concentrations of IgG in colostrum-fed foals and calves decrease steadily until approximately 
four to six weeks of age, after which time IgG concentrations begin increasing again (Boyd, 
1972; Wichtel et al., 1991). 
Passively acquired antibody also exerts immunosuppressive effects in neonates. 
Endogenous IgG production in foals fed bovine colostrum is not detected before 28 d of age 
(Lavoie et al., 1989); whereas, endogenously produced IgG is detected in colostrum-deprived 
foals after 7 d of age and increases rapidly until reaching levels of 10 g/L by 102-135 d of 
age (Holmes and Lunn, 1991). Significant endogenous production of IgG and IgM begins 
around day 8-16 in colostrum-fed calves, while production of IgA isn't detected until day 64. 
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Concentrations of IgM and IgA are almost undetectable before endogenous production 
begins (Husband et al., 1972). Colostrum-deprived calves and foals also attain higher levels 
of endogenous IgG sooner than colostrum-fed animals (Jeffcott, 1974a; Husband and 
Lascelles, 1975). 
Clover and Zarkower (1980) reported a decrease in peripheral blood lymphocyte 
response to mitogens at 6 and 12 h of age in colostrum-fed calves. However, a similar 
response was seen in non-stimulated control lymphocytes obtained from calves at the same 
age, suggesting a general decreased lymphocyte responsiveness at this age. Immunoglobulin 
Gi and G% positive cells are present throughout the peripheral and mesenteric lymph nodes in 
colostrum deprived and mid-term fetal calves. In contrast, no IgGi or IgGa positive cells are 
detected in lymph nodes of colostrum-fed calves. The number of IgA and IgM positive cells, 
however, are similar in all calves (Aldridge et al., 1998). The most abundant immunoglobulin 
bearing cells in lymph nodes of neonatal calves are IgM positive cells (Aldridge et al., 1998), 
and there is a rapid increase in serum IgM concentrations of foals during the first month of 
life (Lavoie et al., 1989). 
Colostrum-fed foals and calves are unresponsive to vaccines containing antigens to which 
high concentrations of maternal antibodies have been acquired (Husband and Lascelles, 
1975; Van Maanen et al., 1992; Wilson et al., 2001; Munoz-Zanzi et al., 2002). However, 
age is also a factor, as colostrum-deprived calves are less responsive to vaccination at birth 
compared to calves vaccinated at four months of age. Colostrum-fed calves vaccinated with a 
novel protein (egg albumin) are able to mount a similar antibody response to colostrum-
deprived calves (Husband and Lascelles, 1975). 
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Leukocytes and Complement Activity 
Leukocyte antibacterial activity is not different between healthy human neonates and 
adults (Wright et al., 1975). Leukocyte antibacterial activity and polymorphonuclear 
lymphocyte (PMNL) chemotaxis in neonates is not affected by gestation length, birth weight, 
use of steroids, type of delivery (C-section, vaginal, local or general anesthesia), Apgar score, 
or neonatal therapy (antibiotics, calcium, assisted ventilation) (Wright et al., 1975; Krause et 
al., 1986). However, leukocytes from stressed neonates have reduced antibacterial activity 
compared to healthy neonates or adults (Wright et al., 1975). Also, PMNL chemotactic 
response is decreased in stressed neonates compared to healthy neonates or adults, but PMNL 
chemotaxis increases in stressed neonates during recovery (Krause et al., 1986). In contrast, 
PMNL adherence values are not different between healthy and stressed neonates; however, 
both values are decreased compared to adults (Krause et al., 1986). 
Newborn calves (prior to colostrum ingestion) have higher total leukocyte counts than 
three to nine week old calves or adult cattle. The percentage of PMNL is higher, but 
percentages of monocytes and lymphocytes are lower (Zwahlen and Roth, 1990; Menge et 
al., 1998). Leukocyte counts do not change significantly after colostrum ingestion (Menge et 
al., 1998). However, total leukocytes, total lymphocytes and all lymphocyte subsets 
measured increase with age from birth through 120 d in foals (Smith et al., 2002). 
Some aspects of neutrophil function are altered in the neonatal calf, lamb, and foal. Foal 
serum has lower opsonic capacity for neutrophils compared to adult serum through 14 d of 
age. Opsonic activity for yeast increases with age, and by three to four weeks, foal serum 
produces similar neutrophil phagocytosis compared to adult serum (Grondahl et al., 1999; 
Demmers et al., 2001). LeBlanc and Pritchard (1988) reported foal serum containing < 3.5 
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g/L of IgG has lower opsonizing activity compared to adult serum, whereas foal serum with 
> 6 g/L of IgG is similar in opsonizing activity compared to adults. Opsonic capacity of foal 
serum is greatly increased by colostrum ingestion, and postcolostral serum is able to opsonize 
E. coli to the same extent as adult serum (Grondahl et al., 2001). Lamb serum also provides 
decreased phagocytosis, with opsonic activity increasing after colostrum ingestion 
(Bemadina et al., 1991). Foal and lamb neutrophils have increased phagocytic ability when 
adult serum or IgG is used for opsonization, demonstrating that neonatal serum is the 
reducing factor for neutrophil phagocytosis in young animals (Bemadina et al., 1991; 
Grondahl et al., 1999). 
Neonatal bovine neutrophils show enhanced migration compared to adult neutrophils 
(Zwahlen and Roth, 1990). Polymorphonuclear lymphocytes in newborn calves are unable to 
recognize and phagocytize bacteria as quickly as three to nine week old calves; however, 
monocytes have increased phagocytic abilities compared to three to nine week old calves. 
Ingestion of colostrum appears to decrease the time needed by phagocytic cells to recognize 
and ingest bacteria (Menge et al., 1998). 
Neutrophil phagocytotic index increases and killing percent decreases from birth until 
approximately 113 d of age in foals, at which time these trends reverse. However, both 
indices were within the range for normal adult horses at all time periods (Wichtel et al., 
1991). Foal neutrophils prior to suckling and at 28 d produce less chemiluminescence (CL) 
than adult neutrophils; however, at 14 d foal neutrophils produce more CL than adult 
neutrophils (LeBlanc and Pritchard, 1988). In contrast, Demmers et al. (2001) reported 
significantly lower neutrophil CL in foals at 2 d and 14 d of age compared to mature cells. In 
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this same study, neutrophil CL in foals that were three months of age or older was equal to or 
higher than mature horses. 
All components of both the classical and alternative complement pathways are present in 
the newborn calf as evidenced by ability to hemolyze red blood cells. However, complement 
activity in both the alternate and classical pathway is decreased in newborn calves compared 
to their dams (Renshaw and Everson, 1979). Concentration of complement component C3 in 
calves at birth is approximately 28% of values observed in adult cows and is not changed by 
feeding colostrum. Concentrations increase significantly during the first month; however, 
they are still less than half of values observed in adult cows (Mueller et al., 1983). 
Effects of Colostrum in the Neonate 
First lactation cows produce significantly lower volumes of colostrum and lower amounts 
of colostral IgG compared to second or later lactation cows. More specifically, first lactation 
cows provide colostrum yields of 3.32 kg, containing 167 g (49 mg/ml) IgG, cows in their 
second to fourth lactation yield 8.10 kg containing 448 g (65 mg/ml) IgG, and cows in their 
fifth lactation or greater yield 6.74 kg and 445 g (86 mg/ml) IgG (Levieux and Oilier, 1999). 
However, others have reported that colostral IgG content does not differ between first and 
third lactation cows (Oyeniyi and Hunter, 1978; Pritchett et al., 1991). The weight of first 
colostrum is also negatively correlated with IgG concentration (Pritchett et al., 1991). 
Besides high concentrations of IgG, first milking colostrum is higher in gross energy, 
crude protein, crude fat, y-glutamyltransferase, aspartate aminotransferase, lactate 
dehydrogenase, and glutamate dehydrogenase compared to milk replacer (Hammon and 
Blum, 1998; Kuhne et al., 2000; Hammon and Blum, 2002). First milking colostrum also 
contains approximately 20-25% more IGF-I, IGF-II, and insulin than mature milk (Odle et 
al., 1996; Kuhne et al., 2000; Hammon and Blum, 2002). 
Colostrum-deprived calves have lower serum concentrations of y-glutamyltransferase, 
aspartase aminotransferase, lactate dehydrogenase, and glutamate dehydrogenase after 
feeding compared to colostrum-fed calves; this change most likely reflects the high levels of 
these enzymes in colostrum (Kurz and Willett, 1991; Hammon and Blum, 1998; Rauprich et 
al., 2000). Kurz and Willett (1991) classified changes in lactate dehydrogenase as 
physiological changes relating to age, rather than relating to colostrum consumption. 
Concentrations of growth hormone (GH) and IGF-1 are not different between calves fed 
colostrum or milk replacer (MR) during the first day of life. However, on day 2, calves that 
receive MR have lower IGF-1 concentrations compared to calves fed colostrum (Hadom et 
al., 1997; Kuhne, et al., 2000). Insulin-like growth factor-1 concentrations in calves fed MR 
also decrease over the first 2 d of life, whereas calves fed colostrum maintain constant IGF-1 
concentrations (Kuhne et al., 2000). In contrast, Rauprich et al. (2000) found plasma IGF-1 
concentrations decreased over the first three days after birth in both colostrum and MR-fed 
calves. 
Calves fed colostrum during day 1 have higher plasma phospholipid, cholesterol, 
carotene, and a-tocopherol concentrations at day 2, 3, 4, and 7, and plasma retinol 
concentrations are higher on day 2 and 3 compared to calves fed water or a glucose solution 
on day 1. Fat soluble vitamin, but not water soluble vitamin concentrations are also altered 
for the first 7 d of life in calves fed colostrum compared to colostrum-deprived calves (Blum 
et al., 1997). 
Colostral leukocytes are also absorbed intact and contribute to neonatal immunity. 
Colostral leukocytes migrate intercellularly between duodenal and jejunal epithelial cells, but 
not ileal cells (Williams, 1993). Leukocytes are absorbed in greater quantities through jejunal 
Peyer's patches than through ileal patches and are observed passing to Peyer's patches 
through the follicle-associated epithelium (FAE). No labeled cells are detected in the 
epithelium outside the FAE (Liebler-Tenorio et al., 2002). In contrast, peripheral blood 
mononuclear cells harvested from the sow and fed to piglets are not absorbed into the 
circulation from the intestine (Williams, 1993). 
Colostral leukocytes absorbed by neonates are able to exert immunomodulating effects. 
Piglets fed colostral leukocytes have higher T-cell responses and significant stimulation of B-
cells compared to piglets not receiving colostral leukocytes (Williams, 1993). Calves infected 
with E. coli and receiving colostrum supplemented with colostral leukocytes shed fewer 
bacteria after infection than those calves receiving colostrum devoid of colostral leukocytes. 
Leukocyte supplemented calves also have higher total antibodies against E. coli by 2 d of age 
than calves fed colostrum devoid of colostral leukocytes (Riedel-Caspari, 1993). 
Colostrum can have profound effects on development of the neonatal intestine. Villus 
circumference, area, and height and height/crypt depth ratio in the duodenum are greater in 
calves fed colostrum for at least the first three days after birth compared to colostrum-
deprived calves or calves fed colostrum for 3 d or less (Buhler et al., 1998; Blattler et al., 
2001). Blatter et al. (1998) observed no differences in the jejunum or ileum, whereas Buhler 
et al. (2001) observed differences throughout the intestine. 
Cell turnover in the intestine is affected by feeding colostrum. Calves that are fed 
colostrum for the first 7 d of life have lower cell proliferation in the duodenum and ileum 
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compared to calves fed colostrum for 3 d. Colostrum-deprived calves also have lower cell 
proliferation in the duodenum compared to calves fed colostrum for 3 d (Blattler et al., 2001). 
Total small intestinal villous circumferences, areas, and heights, are lower in calves 
injected with recombinant bovine GH compared to calves either fed or injected with IGF or 
fed colostrum alone. Thus, postnatal gut development in colostrum fed calves is not 
enhanced by administration of IGF or GH (Buhler et al., 1998). However, Rauprich et al. 
(2000) reported increased xylose uptake in calves fed colostrum compared to calves fed 
formula that contained only 15% of the IGF-I content of colostrum. 
Binding sites for IGF-I and IGF-II are present in the intestinal mucosa of neonatal calves, 
with the greatest concentration of IGF-I sites in the distal intestine (ileum and colon) and 
IGF-II in the duodenum and colon. The number of binding sites for IGF-II is approximately 
17 times greater than IGF-I in the newborn calf intestine, and decreases to five-times greater 
than IGF-I in 8 d old calves (Hammon and Blum, 2002; Georgiev et al., 2003). After birth, 
data for IGF-I and IGF-II in intestinal tissue is conflicting. Calves fed colostrum have a 
reduction in IGF-II binding sites in the ileum of the intestine at 7 d of age compared to calves 
fed MR with added globulins or MR with added rhIGF-I, suggesting that colostrum down-
regulates IGF-II receptors in intestinal tissue (Baumrucker et al., 1994). In contrast, Hammon 
and Blum (2002) found an increase in numbers of IGF-II binding sites for calves fed 
colostrum for 3 d compared to colostrum-deprived calves. The number of IGF-I binding sites 
throughout the intestine was also higher in 8 d old calves fed colostrum for 3 d compared to 
calves fed colostrum at only one feeding and for colostrum-deprived calves (Hammon and 
Blum, 2002). Most recently, Georgiev et al. (2003) reported that IGF-I and IGF-II binding 
capacity was not affected by differences in nutrition in young calves. 
Colostrum-deprived calves have lower dipeptidyl peptidase activity and higher maltase 
activity in the jejunum compared to calves fed colostrum for 3 d. Enzyme activity is not 
different between calves fed colostrum for 3 d and those fed colostrum for 7 d (Blattler et al., 
2001). In contrast, pancreatic lipase activity and trypsin and elastase II activity are higher in 
calves fed colostrum for 7 d compared to calves fed colostrum for 3 d. There were no 
differences in pancreatic activity between calves fed colostrum for 3 d and colostrum-
deprived calves (Blattler et al., 2001). 
These differences between colostrum-fed and colostrum-deprived calves may ultimately 
affect gut absorptive ability. Calves fed colostrum have higher plasma xylose concentrations 
after administration of 0.5 g xylose/kg body weight than calves fed milk replacer, suggesting 
enhanced absorptive capabilities in colostrum fed animals (Hammon and Blum, 1997; Kuhne 
et al., 2000). 
Failure of Passive Transfer (FPT) 
Babies born at 32 weeks of gestation or earlier have circulating IgG concentrations below 
4 g/L due to decreased placental transfer of IgG from the mother to the fetus (Hobbs and 
Davis, 1967). Babies with circulating IgG concentrations < 4 g/L have an increased incidence 
of severe infection compared to those infants with IgG concentrations > 4 g/L (Hobbs and 
Davis, 1967; Sandberg et al., 2000). 
Colostrum is vital to the health and survival of neonatal calves and foals, and 18% of 
dairy cows provide colostrum with a total yield of less than 100 g of IgG, the commonly 
recommended amount needed to prevent failure of passive transfer in calves (Levieux and 
Oilier, 1999). Colostrum deprived calves are 50-75 times more likely to die before 21 d of 
age than colostrum fed calves, with most deaths occurring during the first week of life (Smith 
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and Little, 1922; Crowley et al., 1994; Wells et al., 1996). The risk of death for foals is also 
greatest during the first seven days after birth, with most deaths during this period 
attributable to septicemia (Cohen, 1994). 
Calves, foals, and piglets with low IgG concentrations are at increased risk of morbidity 
and mortality (Boyd, 1972; McGuire et al., 1977; Frerking and Aeikens, 1978; Tyler et al., 
1990; Clabough et al., 1991; Wittum and Perino, 1995; Rea et al., 1996; Donovan et al., 
1998). The IgG threshold for FPT is questionable, and concentrations of < 5 g/L to < 12 g/L 
have been reported to be associated with increased disease and death (McGuire et al., 1977; 
Robison et al., 1988; Clabough et al., 1991; Wittum and Perino, 1995; Rea et al., 1996; 
Donovan et al., 1998). Virtala et al. (1999) reported that calves with serum IgG 
concentrations less than 12 g/L are two-times more likely to suffer from respiratory disease 
during the first three months of life than calves with IgG concentrations >12 g/L. A general 
classification for FPT is < 4 g/L for foals and < 8 g/L in calves (McGuire et al., 1977; 
Clabough et al., 1991; Wittum and Perino, 1995). 
Thirty-one percent of foals have serum IgG concentrations < 8 g/L and 15-18% of foals 
have IgG concentrations < 4 g/L when sampled between 12-72 h (Clabough et al., 1991; 
Stoneham et al., 1991). Morris et al. (1985) reported the incidence of FPT was 2.9% in foals; 
however, this low value is explained by the fact that colostrum was provided by tube or 
bottle within 3 h of birth to foals in the study that either had trouble standing or nursing. 
As stated earlier, calves and foals with low IgG concentrations are at increased risk for 
disease. All foals treated for neonatal infection, which could be attributable to colostral 
immunity, had serum IgG levels < 8 g/L (Stoneham et al., 1991). Colostrum-deprived calves 
have increased scour scores and decreased average daily gain compared to colostrum-fed 
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calves (Crowley et al., 1994). This increase in morbidity also results in lower weaning 
weights in calves with inadequate IgG concentrations at 24 h of age (Wittum and Perino, 
1995). 
Failure of passive transfer in foals is highly correlated to colostral specific gravity (FPT> 
with specific gravity <1.06) and mare age (FPT > when mare age is > 15 yrs). Colostral 
specific gravity is highly correlated to IgG concentration, and mean colostral specific gravity 
and IgG concentration is greatest in mares 3-10 years old (LeBlanc et al., 1992). Failure of 
passive transfer in foals is also associated with the season foaled, type of delivery, gestation 
length, placental expulsion time, parity, and age of mare, listed in decreasing order of 
association (Clabough et al., 1991). Farms that assess passive immunity of foals also have 
lower morbidity; however, mortality rates are not different (Cohen, 1994). This is likely a 
management issue, as farms that assess passive immunity are also apt to aggressively manage 
ill animals. 
Factors present in colostrum other than immunoglobulin molecules also aid in prevention 
of disease. Calves fed colostral Ig preparations containing IgG, IgA, or IgM alone 
experienced increased severity of disease in response to E. coli challenge compared to 
colostrum fed calves. However, colostral preparations were beneficial for reducing severity 
of disease when compared to calves fed colostral whey (Logan et al., 1974). 
Exogenous Passive Immunity 
Oral Colostral Supplements and Replacers 
Oral colostral supplements (CS) and replacers (CR) are available and can be offered 
when either the dam's or other fresh or frozen colostrum source is not available. Colostrum 
supplements are preparations intended to provide < 100 g of IgG/dose and are not formulated 
to replace colostrum. On the other hand, colostrum replacers contain > 100 g IgG/dose and 
provide additional nutrients required by the calf (Quigley et al., 2002b). Bovine colostrum 
can be used as a CS or CR for newborn foals and lambs. Foals fed 1-2 L of bovine colostrum 
attained peak serum IgG concentrations of 18-34 g/L (Holmes and Lunn, 1991), while lambs 
fed 50 g of bovine colostrum replacer had circulating bovine IgG concentrations of 66 g/L 24 
after birth (Quigley et al., 2002a). However, bovine IgG, when fed to colostrum-deprived 
foals, has a serum half life of 7.4-9.6 days, which is much shorter than the half life for equine 
IgG (Lavoie et al., 1989; Holmes and Lunn, 1991). In contrast, bovine IgG supplied to lambs 
does not appear to be metabolized faster than ovine IgG (Quigley et al., 2002a). 
Purified immunoglobulin can also be added to supplement poor quality colostrum, 
however, effects appear to be influenced by IgG source and mass of IgG provided. Morin et 
al. (1997) found no difference in serum IgG concentrations through 48 h of age in calves fed 
poor quality colostrum, or poor quality colostrum supplemented with either 136 g or 272 g of 
a dried colostrum supplement. Apparent efficiency of absorption for IgG is also lower (18% 
vs. 32%) for calves receiving poor quality colostrum supplemented with 272 g of a dried 
colostrum supplement compared to calves receiving poor colostrum only. Calves fed 
colostrum only received 102.8 g IgGl in 12 h, while calves in the supplement group received 
142.4 g and 185.2 g IgGl, respectively (Morin et al., 1997). Calves fed milk replacer 
supplemented with 50 g/L bovine IgG (25 g/L fed with 4 h after birth and again 4-6 h later) 
had serum IgG levels below 7 g/L throughout the 42 d experiment (Crowley et al., 1994). In 
contrast, medium and low quality maternal colostrum supplemented with bovine serum to 
provide equal total IgG concentrations to high quality colostrum alone have increased AEA 
at 24 h in calves (high quality-25%, medium quality-37%, low quality-38%). Calves 
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receiving medium and low quality supplemented colostrum also have higher serum IgG 
concentrations at 12 and 24 h of age compared to calves receiving high quality colostrum 
(Arthington et al., 2000b). 
Calves fed 500 g of whey protein concentrate (WPC) either alone or in 1 L of pooled 
colostrum have lower serum IgG concentrations between 24-36 h and at three weeks of age 
compared to control calves (Mee et al., 1996). Also, mortality rate was higher and BW gain 
lower for calves receiving 500 g of WPC compared to calves receiving colostrum. However, 
there was no difference in mortality rate or BW gain for calves receiving 2 L of colostrum or 
1 L of colostrum supplemented with 500 g WPC (Mee et al., 1996). The addition of whey 
protein concentrate or casein to colostrum supplement products does not appear to affect IgG 
absorption in neonatal calves unless the amount of total protein intake exceeds 500 g 
(Davenport et al., 2000). 
Addition of immunoglobulin supplements to colostrum can also change absorption 
kinetics. Calves provided with colostrum that contains an additional 14 g of immunoglobulin 
supplement at birth and again 12 h later have alterations in IgGi concentration. 
Concentrations of IgGi in control calves peaks at 24 h of age and then decreases, whereas 
concentrations for supplemented calves does not change after peaking at 12 h of age (Abel-
Francisco and Quigley, 1993). 
Apparent efficiency of absorption of CS and CR varies widely based on product 
formulation. Apparent efficiency of absorption of IgG for calves fed maternal colostrum 
(MC) (200 g IgG), CS from bovine serum (90 g IgG), or two CS from milk-derived IgG (50 
g and 60 g IgG) was higher for calves fed CS from bovine serum compared to MC or milk 
protein at 50 g of IgG (Arthington et al., 2000a). The AEA of IgG for bovine serum derived 
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products ranges from 20-33% (Quigley et al., 2000; Quigley et al., 2001; Quigley et al., 
2002b). When equal masses of IgG are fed, serum IgG concentrations were higher in calves 
receiving bovine serum compared to colostrum or porcine serum (Arthington et al., 2000b). 
Apparent efficiency of absorption of IgG in CR can also be affected by the amount of 
IgG fed. In comparison to MC, AEA is reduced when 750 g of CR is fed and increased when 
266 g of CR is fed (Quigley et al., 1998). A CR derived from bovine Ig concentrate and 
providing 122 g of IgG resulted in plasma Ig levels at 24 h of 9.9-11 g/L when fed once 
immediately after birth and 12-14 g/L when fed twice; immediately after birth and at 8 h of 
age. In this same study, AEA was 29-32% when fed once and 19-20% when fed twice 
(Quigley et al., 2001). The addition of fat to CR does not affect IgG absorption (Quigley et 
al., 2001). Also, varying pH of colostral supplements between 7.5 and 5.0 does not influence 
AEA for IgG in calves (Quigley et al., 2000). 
Calves administered three different commercial CS providing a total mass of IgG of 156, 
107, and 126 g had lower IgG concentrations at 24 h and 48 h after birth, lower AEA, and 
more episodes of disease compared to calves fed maternal colostrum (total IgG mass of 164 
g) (Garry et al., 1996). In contrast, other researchers have found that supplemental IgG can 
be provided to decrease severity of disease. Supplementation of milk replacer with bovine 
plasma powder decreased severity of clinical signs and increased survivability of calves 
infected with E. coli (Nollet et al., 1999). Calves infected with coronavirus and fed 
supplemental bovine serum were less dehydrated and maintain higher feed intakes compared 
to control calves (Arthington et al., 2002). Finally, calves provided with antibody against 
bovine coronavirus from egg yolk had lower mortality, lower fecal scores, and increased 
weight gains after coronavirus infection compared to calves that did not receive antibody 
(Ikemori et al., 1997). 
An oral equine serum product provided to foals within 4 h after birth (two doses 1-2 h 
apart) produced plasma IgG concentrations at 24 h of 1.05 g/L, which was well below values 
in control foals (39 g IgG/L) (Vivrette et al., 1998). However, foals allowed to suckle their 
dams and given two 150 ml doses of an equine serum product had higher serum IgG levels 
the day after treatment compared to foals that only suckle (19.4 g IgG/L treated vs. 12.4 g 
IgG/L control) (Davis et al., 1995). 
Foals fed 250 ml lyophilized equine serum (5,400 mg of IgG/100ml) within 4 h after 
birth had similar serum IgG levels at 24 h of age compared to foals fed 250 ml of colostrum 
(7,200 mg of IgG/100ml) (Burton et al., 1981). Colostrum deprived foals given lyophilized 
purified equine IgG orally in 10 g units (diluted in 5% dextrose to 125 ml) at various times 
after birth have also been studied. Serum IgG concentrations of these foals did not differ 
whether they were given a total of 50 g, 60 g or 70 g of IgG. Concentrations of serum IgG 
were similar at 2 h, regardless of the initial amount of IgG given (range 10-30 g). 
Unfortunately, none of the dosing regimes provided serum IgG levels >5 g/L at 24 h of age 
(Franz et al., 1998). In general, a dose of 10 g of lyophilized IgG/15 kg body weight provided 
to foals after birth results in a mean serum IgG concentration of approximately 4 g/L at 14 h 
(Franz et al., 1998). 
Injectable Immunoglobulin (calves and foals) 
Once the period of intestinal permeability to immunoglobulin molecules has passed, 
passive immunity can be provided through intravenous (IV), intraperitoneal (IP), or 
subcutaneous (SQ) injection. Colostrum-deprived calves provided with 20 ml plasma/kg BW 
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intravenously have increases in total immunoglobulin of 262 mg %, in IgG, of 192 mg %, in 
IgG2 of 66 mg %, in IgM 4 mg %, and in IgA of 0 mg% at 24 h. If given IP, total 
immunoglobulin increases 268 mg%, IgG, increases 192 mg %, IgGa increases 66 mg %, 
IgM increases 6 mg %, and IgA again increases 0 mg % at 24 h. However, values for 
circulating IgG concentrations were still below the protective level as evidenced by an 
increased prevalence of illness and lower average daily gain when compared to calves fed 
maternal colostrum (Anderson et al., 1987). 
Subcutaneous injection of bovine plasma or purified plasma IgG containing 47 g or less 
of IgG does not raise plasma IgG levels in calves (Crowley et al., 1994; Quigley and 
Welbom, 1996). In contrast, calves provided with an IV infusion of a bovine plasma product 
containing 47 g IgG had increases in serum IgG of 2.9 g/L with an apparent infused IgG 
retention of 32%. However, mean BW gain, mortality and medical treatments were not 
affected by treatment in calves receiving IgG either by IV or SC injection (Quigley and 
Welbom, 1996). 
Immunoglobulin G provided by intravenous infusion to calves and foals has a serum half-
life of 18 - 23 d (Reilly and Macdougall, 1973: Besser et al., 1988). Approximately 1.5% is 
excreted daily in the feces, and 2.5% is excreted daily in the urine. It is estimated that 68% of 
the IgGi administered is transferred to the gastrointestinal tract (Besser et al., 1988). 
Colostrum-deprived foals given an IV immunoglobulin (IVIG) concentrate containing 20 
g or 30 g of equine IgG at a rate of 100 ml/10 min had serum IgG concentrations of 4.3 g/L 
and 7.7 g/L at 24-48 h post-infusion, respectively. The IgG concentration of the product was 
10 g/100 ml, with foals receiving 200 ml and 300 ml, respectively (Liu et al., 1991). Brown 
et al. (1991) reported foals provided with IVIG containing 20 g, 30 g or 40 g of IgG had 
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average increases in serum IgG concentrations of 2.75 g/L, 3.40 g/L, and 4.84 g/L, 
respectively. Intravenous administration of 10 g lyophilized equine IgG diluted in 400 ml of 
5% dextrose increased foal serum IgG concentrations by 2-3 g/L (Franz et al., 1998). Foals 
with variable initial IgG levels (1.95-6.58 g/L) had a mean increase in serum IgG levels of 
4.82 g/L after receiving 3 L of IV equine plasma containing 12-16 g IgG/L (Brown et al., 
1991). Serum IgG concentrations at 12 h post IV infusion are inversely related to foal body 
weight (Franz et al., 1998). 
A minimum of 10 g of donor IgG should be administered IV to foals older than 1 d of age 
to raise serum IgG levels by 1 g/L (Stoneham et al., 1991). Pony foals administered equine 
plasma IV at a rate of 15 ml/kg after birth had serum IgG concentrations greater than 800 
mg/dl at 24 h of age (Perkins et al., 2001). 
Health status of the animal at the time of IVIG administration also affects outcome. 
Colostrum-deprived healthy foals provided IV equine plasma can be predicted to have an 
elevation in serum IgG of 8.68 mg/dl/g IgG administered/kg BW, where as clinically ill foals 
will have an elevation of 6.16 mg/dl/g IgG administered/kg BW, suggesting an increase in 
IgG metabolism or consumption by the ill foal (Wilkins and Dewan-Mix, 1994). 
Pony foals provided with intravenous hyperimmune plasma containing R. equi antibodies 
had greater titers to R. equi 7 d after infusion compared to foals receiving normal plasma 
(Perkins et al., 2001). Surprisingly, mortality rate, duration of illness, and clinical parameters 
were not different between pony foals receiving hyperimmune R. equi or normal equine 
plasma that were infected with R. equi (Perkins et al., 2001). 
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Injectable Immunoglobulin (humans and lab animals) 
Intravenous immunoglobulin is commonly used in human medicine to treat a variety of 
disorders and is reported to have a half-life of 24-30 d (Andresen et al., 2000). Intravenous 
immunoglobulin is purported to exert immunomodulatory properties in humans via the 
following mechanisms: 1) functional blockade of Fc receptors on splenic macrophages; 2) 
inhibition of complement damage by IgG binding of C3b and C4b fragments; 3) modulation 
of the production of cytokines; 4) neutralization of circulating autoantibodies; and 5) 
selection of immune repertoires (Andersson et al., 1996; Basta, 1996; Mouthon et al., 1996). 
A study examining over 230 samples from commercially available human IVIG 
preparations detected no evidence of interleukin (IL)-6, IL-10, or tumor necrosis factor-a 
(TNF-a) in any of the preparations. However, high levels of transforming growth factor-(3 
(TGF-P) were detected in all samples (Kekow et al., 1998). Neutralizing antibodies 
(specifically IgG) against the cytokines granulocyte-macrophage colony-stimulating factor, 
interfeuron-a (IFN-a), and IL-1 were also detected in over 70% of human immunoglobulin 
preparations tested. Neutralization of IL-2, IL-3, IL-4, IL-6, IL-9, IL-10, IL-12, TNF-a, and 
IFN-y was not detected (Wadhwa et al., 2000). 
Transforming growth factor-P concentrations increase in patients receiving IVIG; this is 
attributable to the high level of TGF-P contained in IVIG preparations (Kekow et al., 1998). 
However, the immunosuppressive effects of IVIG in vitro are not due to TGF-P, as inhibitory 
effects are not removed by addition of neutralizing antibody (Schaik et al., 1998). 
Patients with primary hypogammaglobulinemia have elevated levels of several 
components of the IL-1 system, IL-1 receptor antagonist, and of neutralizing IL-la 
antibodies. Peripheral blood mononuclear cells (PBMC) from these patients also release 
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elevated levels of IL-1. Infusion of IVIG significantly decreased IL-1 levels in these patients, 
and PBMC also showed a decrease in the release of IL-1 (Aukrust et al., 1999). Serum 
obtained from IVIG patients after infusion also showed impaired IL-la- and IL-1(3-
stimulated release of TNF-a from PBMC compared to that of serum collected prior to 
infusion (Aukrust et al., 1999). 
Infusion of either IVIG or Fabz fragments inhibits TNF-a secretion from PBMC in vitro 
(Menezes, et al., 1997). In contrast, others have reported IVIG preparations inhibit in vitro 
PBMC proliferation and IL-4 secretion, but not IFN-y or TNF-a (Andersson, et al., 1996; 
Campbell et al., 1999). 
Human immunoglobulin, Fabz, and Fc fragments all inhibit proliferation of PBMC in 
vitro; IgG and Fab2 fragments inhibit generation of cytotoxic T cells; and IgG and Fc 
fragments suppress natural killer cell lysis of target cells (Nachbaur et al., 1997). 
Immunomodulatory effects of human IVIG in vitro are attributable to IgG inhibition of T-cell 
proliferation and generation of cytotoxic T lymphocytes, and reduced IL-2 levels. Unchanged 
levels of IL-2 mRNA in IVIG supplemented cultures suggest that IVIG regulates IL-2 post-
transcriptionally (Nachbaur et al., 1997). 
Infants born after 32 weeks gestation or less have circulating IgG concentrations < 4 g/L 
have an increased incidence of severe infection compared to those infants with IgG 
concentrations > 4 g/L (Hobbs and Davis, 1967; Sandberg et al., 2000). Intravenous 
immunoglobulin is suggested as a method to increase disease protection; however, infants 
born with IgG levels < 4 g/L and receiving IVIG had no reduction in morbidity or mortality 
when compared to infants born with IgG levels < 4 g/L and given a placebo (Sandberg et al., 
2000). 
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In contrast, immunoglobulin administered IP appears to increase survival in mice infected 
with type III Group B streptococcus (GBS), a common infectious agent in human infants. 
Mortality rates in newborn rats infected IP with GBS was 93% without treatment. Mortality 
rates were 0% when the rats were injected with hyperimmune human IgG IP at a dose of 140 
mg IgG/kg immediately after GBS injection and at 30 min and 2 h post GSB injection. 
Mortality rates also decreased when IP IgG was given at 6 h and 12 h post GSB injection, but 
not 18 h post GSB injection (Givner and Nagaraj, 1993). 
Immunoglobulin Products and Manufacturing 
Plasma fractionation described by Cohn et al. (1946) is commonly used to isolate 
immunoglobulins. Using ethanol precipitation, Fraction II (FII) of this method contains the y-
globulins. Fractionation of human plasma using Gradiflow technology to purify IgG has also 
recently been described and recovers 95% of the IgG with high purity (Li et al., 2002). 
Other methods of immunoglobulin separation have been described. Polyphosphate 
precipitation can be used to separate crude immunoglobulin from bovine plasma. 
Immobilized copper affinity chromatography or DEAE-Sephacel ion-exchange 
chromatography is then used to further purify the crude immunoglobulin. Immobilized 
copper affinity chromatography recovers approximately 40% of the IgG with a purity of 
99%, while DEAE-Sephacel ion-exchange recovers 30% of the IgG with a purity of 100% 
(Lee et al., 1988). 
Purified immunoglobulin for injection must be stabilized, and the pH and protein 
concentration must be adjusted prior to administration. An example is a liquid human IVIG 
prepared from plasma by Cohn FII, stabilized in sorbitol and with pH adjusted to 5.0. The 
protein concentration is then adjusted using 0.5 M HC1 and 0.3 M glycine (Sisti et al., 2001). 
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Purified immunoglobulin can also be lyophilized. Lyophilized human IgG can be 
prepared from plasma by Cohn FII and stabilized with sucrose. Sodium concentration is 
adjusted to 120 mEq/L with 1.0 M NaCl, and pH adjusted to 7.0 using 10% NaCHOg. The 
protein concentration is adjusted to 10% using 0.3 M glycine. The lyophilized product is 
reconstituted in sterile water prior to injection to provide a 5% IVIG solution (Sisti et al., 
2001). 
Polyethylene glycol (PEG) is a non-antigenic molecule that does not generate antibody 
production when coupled to other proteins (Abuchowski, 1977). When coupled to IgG, PEG 
stabilizes the IgG molecule, decreases complement fixing ability, and suppresses aggregate 
formation. Unfortunately, PEG-coupling also reduces antigen binding ability. PEG-coupled 
IgG with a PEG content of 4 mol/mol IgG retains about 70% of its antigen binding ability 
(Suzuki et al., 1984). 
Polyethylene glycol can also be used to concentrate IgG from plasma (Poison and Ruiz-
Bravo). However, calves fed CR containing bovine IgG concentrated with polyethylene 
glycol to fractionate the IgG from plasma had lower plasma IgG concentrations at 24 h and 
lower AEA compared to calves fed CR containing bovine IgG concentrate that was not 
prepared with polyethylene glycol fractionation (Quigley et al., 2001). 
Water dilution, PEG, dextran sulfate, xanthan gum, and ammonium sulfate precipitation 
have all been described for purification of immunoglobulin (IgY) from egg yolk. Water 
dilution and ammonium sulfate precipitation both provide higher purity and yield when 
compared to the other methods (Akita and Nakai, 1993; Svendsen et al., 1995). 
Reactions to Intravenous IgG infusions 
Unfortunately, adverse reactions to IVIG administration can occur, and may be due to 
anaphylaxis, complement activation, vasoactive properties of the product, or other unknown 
mechanisms. Clinical signs of reactions vary in severity and include hyper- or hypotension, 
tachycardia, increased respiration rate, myalgia, rash, and nausea (Schifferli, 1992; Stangel et 
al., 1997). The clinical signs are usually associated with the release of preformed mediators 
from mast cells and basophils including the release of histamine (Bochner and Lichtenstein, 
1991). Release of histamine is involved in anaphylactic-associated increase in vascular 
permeability, and adversely affects neutrophil infiltration (Hirasawa et al., 2002). Adverse 
reactions to IVIG in humans have also been shown to be associated with increases in IL-6 
and thromboxane B%, without concurrent changes in blood pressure, kininogen, histamine, or 
tryptase (Bagdasarian et al., 1998). 
Incidence of adverse reactions to IVIG is often associated with rapid infusion rate 
(Stangel et al., 1997). With infusion rates of 0.04, 0.06, and 0.08 ml/kg/min for IVIG in 
humans (final dose of 0.5 g IgG/kg body weight), adverse reactions were only noted with the 
highest infusion rate (Bagdasarian et al., 1998). 
Hypotension has been noted in rats administered a human IVIG product, with ranges 
from less than 15% up to a 50% decrease in mean arterial blood pressure (Bleeker et al., 
1997; Bleeker et al., 2000). The long-acting hypotension observed in rats occurred after 1 
min, and did not return to normal within 1-3 h after administration (Bleeker et al., 1987). The 
hypotensive effect was product related and was significantly correlated with the IgG dimer 
content of the IVIG product (Bleeker et al., 2000). Human IVIG products with a high content 
of IgG dimers induce a strong hypotensive effect in rats, however, there is a minimal 
decrease in complement. On the other hand, heat aggregated IgG has little effect on blood 
pressure but leads to a decrease in complement. Thus, hypotension and complement 
activation are independent (Bleeker et al., 1987; Bleeker et al., 1989). 
Dimer formation in IVIG preparations can be influenced by a variety of factors. The IgG 
dimer percentage in IV plasma products increases as the number of donors to the plasma pool 
increases, and some products may contain up to 40% IgG dimers (Tankersley et al., 1988). 
Immunoglobulin G dimer percentage also increases over time during storage, and with 
decreasing pH, increasing temperature, and increasing ionic strength (Tankersley et al., 
1988). 
Human IVIG products that contain elevated amounts of prekallikrein activator (PKA) 
(Hageman factor fragments) and kallikrein cause increased vascular permeability when 
injected into guinea pigs (Alving et al., 1980). Human plasma protein fractions with 
increased PKA concentrations also cause increased generation of bradykinin and decreases in 
mean arterial pressure when infused into rats (Bleeker et al., 1982). However, PKA, infused 
in concentrations equivalent to those found in standard human immunoglobulin preparations 
that caused hypotension in rats, had no effect on blood pressure in rats. A similar lack of 
hypotension was observed after infusion of a lower molecular weight fraction containing 
monomer IgG and 5% dimeric IgG. In contrast, the higher molecular weight fraction 
(containing IgG polymers) caused a strong hypotensive effect. Thus, it can be concluded that 
hypotension in response to IVIG administration was due to IgG aggregates in the preparation 
(Bleeker et al., 1987). 
Immunoglobulin G aggregates prepared from human plasma bind and activate CI 
(complement) in a dose-dependent fashion. Aggregates of 20 IgG molecules bind and 
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activate more Cl molecules/aggregate than IgG monomers. This data showed that 
monomeric IgG binds CI poorly, whereas aggregation promotes binding. Aggregates as 
small as 5 IgG molecules greatly enhanced binding and activation over monomers of IgG 
(Doekes et al., 1982). 
Incubation of human granulocytes with IVIG results in a concentration dependent 
increase in superoxide anion release that is mediated through the FcyR. Granulocytes 
exposed to IgG dimers release more 0{ than those exposed to IgG monomers (Nemes et al., 
2000). 
Reactions to IVIG have also been observed in calves and foals. Calves receiving IVIG 
containing 47 g IgG that was purified and precipitated with (NH^SCU and suspended in 
0.9% NaCl commonly demonstrated signs of transfusion reactions during infusion (Quigley 
and Welbom, 1996). Twenty-five to fifty percent of foals that received IVIG containing 20-
30 g IgG showed mild signs of reaction including increased respiration rate, muscle tremors, 
tachycardia, hyperemic mucous membranes, depression, and mild signs of colic (Brown et 
al., 1991; Liu et al., 1991; McClure et al., 2001). An increased reaction rate is reported for 
foals receiving lyophilized IgG products as well. Fifty-five percent of foals receiving 10 g of 
lyophilized equine IgG showed signs of discomfort during infusion including diarrhea, 
tachypnea, and/or abdominal pain (Franz et al., 1998). 
Reactions to Contrast Media/Hyperosmolar solutions 
Administration of contrast media and hyperosmolar solutions to humans also causes 
reactions similar to those observed from infusion of IVIG. Table 1.2 lists many of the 
solutions/drugs that induce these reactions and the immune mechanisms activated. 
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Most general anesthetics and radiocontrast media induce the release of preformed 
mediators (histamine and typtase) from basophils and mast cells, not synthesized eicosanoids 
(PGD2, LTC4, and PAF) (Genovese et al., 1996). Increasing the osmolality of contrast media 
agents, as well as mannitol, causes an increase in histamine release from basophils (Findlay 
et al., 1981; Stellato et al., 1996). However, different amounts of histamine are released from 
basophils by contrast media in the same osmolality range suggesting that osmolality alone is 
not the sole mechanism influencing histamine release (Stellato et al., 1996). Histamine 
released by basophils in response to hyperosmolar mannitol is not a result of disruption of the 
cell membrane or cytotoxicity, and is independent from binding of IgE (Findlay et al., 1981; 
Findlay et al., 1984). 
Table 1.2. Drugs and radiocontrast media frequently associated with 
anaphylactic/anaphylactoid reactions (Genovese et al., 1996). 
Drug/RCM IgE-Mediated 
Activation 
Complement-
Mediated Activation 
Direct Activation 
Muscle Relaxants + - + 
(tubocurarine, 
suxamethonium, 
atracurium, 
pancuronium, 
vecuronium) 
Hypnotics -
barbiturates 
+ + + 
(Thiopental, 
methohexitone) 
Nonbarbiturate - + + 
hypnotics (Propofol, 
althesin, propanidid) 
Opioids (Morphine, 
buprenorphine, 
fentanyl) 
+/- + 
Plasma expanders 
(Dextran, hemagel) 
-
+ + 
Protamine + + + 
Radiocontrast media +/- + + 
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Anaphylactic Reactions and Prevention 
There are three ways that exposure to a substance can cause anaphylaxis: 1) exposure to a 
foreign protein that results in IgE antibody formation; reexposure results in IgE mediated 
degranulation of mast cells and basophils; 2) formation of immune complexes that activate 
the complement cascade; and 3) administration of certain agents (hyperosmolar solutions, 
radiocontrast agents, etc.) that directly stimulate release of mediators by unknown 
mechanisms (Bochner and Lichtenstein, 1991). Classic anaphylactic reactions are defined as 
resulting from a Type I immune response, also called immediate hypersensitivity. This type 
of reaction requires three components: 1) an antigen; 2) IgE antibody; and 3) effector cells 
such as mast cells and basophils that synthesize and release pharmacologic mediators 
(Carlson et al., 1986). Reactions that appear clinically similar to anaphylactic reactions, but 
are not mediated by IgE are referred to as anaphylactoid reactions (Carlson et al., 1986). 
Mast cells are not necessarily required for anaphylactic shock in the mouse, as mast cell 
deficient mice are able to develop anaphylaxis clinically indistinguishable from that 
exhibited by normal mice (Jacoby et al., 1984; Arimura et al., 1990). Some studies report 
increased concentrations of blood histamine after challenge in control mice (Choi et al., 
1998), while others report no change in histamine levels before or after anaphylaxis in both 
control and mast cell deficient mice (Jacoby et al., 1984). Hypotension and death due to 
anaphylactic reactions in mice also do not appear to require mast cell-derived mediators 
(Martin et al., 1993; Miyajima et al., 1997). 
Systemic responses and mortality associated with anaphylaxis are mediated through 
FcRy; mice lacking the FcRy show no cardiopulmonary changes or mast cell degranulation, 
and do not die after induction of anaphylaxis. A functional FcsRI is also not required for 
mast cell degranulation or mortality associated with anaphylaxis, as mice lacking this 
receptor exhibit responses similar to FcsRI +/+ mice (Miyajima et al., 1997). 
In the mast cell deficient mouse, IgGi sensitizes other cells, resulting in release of platelet 
activating factor (PAF) and leading to the clinical signs of anaphylaxis (Arimura et al., 
1990). Rat peritoneal cells produce PAF in response to either IgE, or IgG complexes. The 
production of PAF is unrelated to mast cell activation and depends on mononuclear cell 
activation via FcsRII or FcRy (Pellon et al., 1993). The release of PAF results in 
hypotension, tachycardia, and circulatory collapse (Goldstein et al., 1991). Changes in mean 
arterial pressure are observed within one minute after intravenous injection of PAF 
(Rabinovici et al., 1991). Intravenous injection of PAF will also cause the death of mice in a 
dose dependent manner (Herbert et al., 1991; Fukuda et al., 2000), and topical application of 
PAF causes pronounced arteriolar vasoconstriction and leakage of FITC-dextran from the 
vascular space in the hamster cheek pouch (Klabunde and Anderson, 2000). 
Incubation with IVIG causes activation of neutrophils and macrophages via Fc receptors 
resulting in PAF release (Bleeker et al., 1989; Teeling et al., 1998; Bleeker et al., 2000). 
Rabbits released increased amounts of PAF into their plasma within 2 min after antigen 
challenge during IgE-induced systemic anaphylaxis, and this release was indistinguishable 
both physiochemically and functionally from PAF released in vitro from IgE-sensitized 
basophils (Pinckard et al., 1979). 
Anaphylactic shock in mast cell deficient mice was suppressed by CV-3988, a specific 
antagonist to PAF, but not by cyproheptadine, an antagonist to histamine and serotonin 
(Arimura et al., 1990). Pretreatment with PAF acetylhydrolase or PAF antagonist blocked 
fatal anaphylactic reactions in both mast cell deficient and control mice (Choi et al., 1998; 
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Fukuda et al., 2000). However, tachycardia in anaphylactic reactions is mediated by mast 
cells in mice, and cannot be prevented by antagonists to histamine, the cyclooxygenase 
metabolites of arachidonic acid, or PAF (Martin et al., 1993). 
SK&F 98625 and SK&F 45905, inhibitors of coenzyme A-independent transacylase, 
caused concentration dependent reduction of PAF in stimulated neutrophils and mast cells 
(Winkler et al., 1996). Intravenous pretreatment with PAF acetylhydrolase completely 
protected mice from death induced by PAF injection (Fukuda et al., 2000). Pretreatment with 
SR 27417 (per os or intravenously) also protected mice from PAF-induced death (Herbert et 
al., 1991). Rupatadine is an orally active dual antagonist of histamine and platelet activating 
factor. This compound exhibited inhibitory effects for both PAF and histamine induced 
hypotension and bronchospasm in rats and guinea pigs (Merlos et al., 1997). 
Conclusion 
Passive immunity is important to neonatal animals for the prevention of disease, and 
there is a great body of literature supporting this fact. Management methods and products 
that significantly enhance passive immunity greatly enhance neonatal survival and decrease 
costs associated with morbidity. There are a variety of commercial products available that 
can be provided orally to calves and foals to increase passive immunity. However, the IgG 
content of many products is quite low, and most fail to increase IgG concentrations above 
levels needed to prevent FPT. Also, there are no commercially available concentrated IgG 
products for IV use in cattle, and minimal research on these types of products has been 
published. 
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CHAPTER TWO 
EFFECTS OF ORAL ADMINISTRATION OF CONCENTRATED EQUINE SERUM 
IGG TO NEWBORN FOALS ON PASSIVE IMMUNITY 
A paper published in the Journal of Equine Veterinary Science1 
C.J. Hammer2, H.D. Tyler3, and P.A. Miller3 
SUMMARY 
Thirteen newborn foals of Quarter Horse breeding were used to determine if oral 
administration of concentrated equine serum increases concentrations of IgG in foals allowed 
to naturally suckle colostrum. Foals were alternately assigned either to receive 300 ml of an 
oral equine serum IgG product or to serve as controls. Foals receiving the IgG product were 
given 150 ml orally at 10 h and again at 12 h after birth. All foals were allowed to suckle 
from their dams ad libitum. Jugular blood samples were obtained from foals at 10 h and 24 h 
of age for IgG determination. Colostrum samples from the dam were also obtained within 3 
h following parturition for determination of specific gravity. Plasma samples were analyzed 
for IgG level using a commercially available radial immunodiffusion kit. Oral administration 
of equine serum IgG had no significant effect on concentrations of plasma IgG in foals at 24 
h of age (p>.34). There was also no difference between control and treated foals in the rate 
of IgG absorption from 10-24 h after birth (p>.34). In conclusion, oral administration of 
equine IgG to foals that ingest their dam's colostrum does not significantly increase 
concentrations of plasma IgG when compared to controls. 
1 Reprinted with permission of the Journal of Equine Veterinary Science, 200, 20(5), 337-338. 
2 Graduate student, primary researcher, and author; Iowa State University, Ames, IA. 
3 Associate Professor; Iowa State University, Ames, IA. 
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INTRODUCTION 
Colostral antibodies are the most important factor providing immunological protection to 
the neonatal foal.1"3 Foals that fail to obtain adequate amounts of these antibodies, those 
classified with failure of passive transfer, are at an increased risk for developing infection 
and(or) death.2'3 Foals with complete failure of passive transfer (IgG < 200 mg/dl) or partial 
failure of passive transfer (IgG 200-800 mg/dl) are often provided additional colostrum or 
colostral supplements when the foal is less than 24 h of age.4 The oral colostral supplement 
tested in this study is commercially available and marketed to consumers not only as a 
treatment for failure of passive transfer, but also as a supplement to enhance antibody levels 
in foals with adequate passive immunity (Sera, Inc., Shawnee Mission, KS). The purpose of 
this study was to determine if an orally-administered concentrated IgG product can enhance 
IgG levels in normal foals that are allowed to suckle their dams ad libitum. 
MATERIALS AND METHODS 
Thirteen foals of Quarter Horse breeding were utilized in this study. All foals were born 
in individual stalls and parturition was attended from the onset of abdominal contractions. 
Foals were alternately assigned either to receive 300 ml of an oral equine IgG product of 
serum origin containing 12,000-15,000 mg IgG/300 ml (Sera, Inc., Shawnee Mission, KS) or 
to serve as a control. Approximately 10 ml of jugular blood was obtained from foals at 10 h 
after birth, centrifuged, and the plasma collected and stored at -20°C. Foals receiving oral 
IgG were given one dose immediately following the 10 h blood collection, and another dose 
at 12 h of age. Each dose of IgG was administered orally in three 50 cc aliquots using a dose 
syringe. A total of 150 ml was provided at each dosage time. Jugular blood samples were 
again obtained at 24 h of age from all foals, and plasma was collected and frozen. IgG 
concentrations were determined by radial immunodiffusion using a commercially available 
kit (VMRD, Inc., Pullman, WA). The rate of IgG absorption (mg of IgG appearing in 
plasma/hr) was calculated to determine if oral supplementation affected this parameter. 
All foals were allowed to suckle ad libitum. Colostrum samples were obtained from each 
mare within 3 h following parturition and specific gravity was determined using a 
colostrometer (Lane Manufacturing, Inc., Denver, CO). 
All data were analyzed using the general linear models procedure of SAS.5 
Immunoglobulin G concentration at 10 h of age was included as a covariable for determining 
differences in concentration at 24 h of age, and rate of IgG absorption from 0-10 h of age was 
included as a covariable for determining differences in rate of absorption of IgG from 10-24 
h of age. One foal in the treated group had difficulty suckling and had to be assisted during 
the first 12 h after birth; this foal was subsequently removed from the study. 
RESULTS AND DISCUSSION 
All foals had IgG concentrations well above 800 mg/dl at 10 h of age (Figure 2.1). In 
colostrum-fed foals, peak plasma IgG levels are obtained at approximately 12 h of age, so the 
decrease reported at 24 h of age for foals in the control group was expected.1 The peak 
occurred closer to 18 h of age in supplemented foals, explaining the apparent increase in 
plasma IgG levels at 24 h of age in the treated foals in this study. 
The specific gravity of colostrum produced by the mares was not different (p>.53) 
between the two treatment groups. Concentrations of IgG were higher for foals in the control 
group at 10 h of age (p<.01), and rate of IgG absorption (Figure 2.2) was increased from 0-10 
h of age (p<.01) compared to that of treated foals. 
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Figure 2.1. Concentrations of IgG prior to (10 h) and following (24 h) oral administration of 
concentrated equine serum derived IgG 
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Figure 2.2. Rate of IgG absorption prior to (0-10 h) and following (10-24 h) oral 
administration of concentrated equine serum derived IgG 
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Although the foals were alternately assigned to treatments at birth, it is possible that by 
chance the more aggressive suckling foals or the foals with more maternal dams ended up in 
the control group. To account for these initial differences, foal plasma IgG concentration at 
10 h and rate of IgG absorption from 0-10 h were included as covariables in the statistical 
analysis. When these differences were accounted for, plasma concentrations of IgG at 24 h 
of age and the rate of absorption of IgG from 10-24 h of age were not statistically different 
(p>.34) between foals in the two groups. 
The results from this study indicate that this oral IgG product was ineffective in raising 
plasma IgG concentrations in foals allowed to suckle their dams ad libitum when 
administered at 10 h and 12 h after birth. A previous research study found that 
administration of this same product did in fact increase concentrations of IgG in foals at 24 h 
of age (treated mean [IgG]= 1935 mg/dl; untreated mean [IgG]= 1241 mg/dl).6 The time of 
administration of the product was not reported, and so it is possible that earlier administration 
may have contributed to the different outcomes. However, other researchers have reported 
that oral administration of concentrated equine serum IgG within 4 h after birth does not raise 
concentrations of serum IgG above 500 mg/dl in colostrum deprived foals.4,7 An increase in 
blood IgG concentrations of 200 - 300 mg/dl in foals with adequate passive immunity (IgG > 
800 mg/dl) would provide minimal physiological improvement in disease resistance. If the 
colostrum supplement contained high enough titers of specific antibody not present in the 
dam's colostrum, then administration may be warranted. In conclusion, use of this product 
for increasing total immunoglobulin concentrations in normal foals suckling mares with good 
quality colostrum would not be beneficial. 
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CHAPTER THREE 
ADEQUACY OF A CONCENTRATED EQUINE SERUM PRODUCT IN 
PREVENTING FAILURE OF IMMUNE PASSIVE TRANSFER IN NEONATAL 
FOALS: A PRELIMINARY STUDY 
A paper published in the Equine Veterinary Journal1 
C.J. Hammer2, J.A. Booth3, L. Etzel4, and H.D. Tyler5 
Summary 
The primary objective of this study was to determine if an orally administered concentrated 
equine serum product provided in the first hours of life could prevent failure of passive 
transfer in foals. To achieve this objective, ten foals of Quarter Horse breeding were utilized. 
Treated foals were administered 250 ml of an oral serum product at 1 and 3 h of age via 
nasogastric intubation. These foals were muzzled to prevent nursing from their dam. 
Supplemental milk replacer (200 ml/feeding) was provided to the treated foals at 6 h and 9 h 
of age. Mares of treated foals had their udder stripped at 1, 3, 6, and 9 h post parturition. 
The initial colostrum collected (200 ml) was fed back to the treated foals when the muzzle 
was removed at 12 h of age. Control foals were allowed to nurse from their dams ad libitum. 
Ten ml jugular blood samples were obtained from all foals (5 treated/5 control) at 1, 3, 5, 7, 
9, 10, 11, 12, 24, and 48 h of age for determination of concentrations of plasma IgG. Plasma 
IgG concentrations were higher (p<.05) for treated foals compared to control foals at 5 h and 
48 h of age. Plasma IgG concentrations were not different (p>.10) at all other time periods 
measured. All treated foals had plasma IgG concentrations over 700 mg/dl by 10 h of age. 
1 Reprinted with permission of the Equine Veterinary Journal, 2001, 33(7), 734-736. 
2 Graduate student, primary researcher, and author; Iowa State University, Ames, IA. 
3 Graduate research assistant; Iowa State University, Ames, IA. 
4 Research Scientist; Proliant, Inc., Ames, IA. 
5 Associate Professor; Iowa State University, Ames, IA. 
66 
Introduction 
Foals are essentially agammaglobulinemic at birth, and ingestion of adequate amounts of 
colostrum is essential to provide the neonatal foal with passive immunity (Jeffcott, 1974). 
Failure to obtain adequate passive immunity occurs in 15% or more of Thoroughbred and 
Standardbred foals, and results in increases in morbidity and mortality (Clabough et al. 1992; 
McGuire et al. 1977; Stoneham et al. 1991). 
In an attempt to increase immunoglobulin levels in foals suffering from partial or 
complete failure of passive transfer (FPT), many oral and intravenous equine 
immunoglobulin supplements have been developed. If a foal is more than 24 hours old, 
intravenous products are the only option for administration, and must contain at least 30 g of 
purified IgG to increase serum IgG concentrations above 700 mg/dl (Liu et al. 1991; Wilkins 
and Dewan-Mix, 1994). If a foal is less than 24 hour old and FPT is confirmed or suspected 
based on history, oral immunoglobulin products can be administered if no banked equine 
colostrum is available. 
Bovine colostrum can be offered and results in serum concentrations of IgG over 1300 
mg/dl. Unfortunately, the half-life of bovine IgG in the foal is much shorter (7.4 - 9.4 d for 
bovine compared to 26 d for equine IgG) (Lavoie et al. 1989; Holmes and Lunn, 1991). 
Also, the ability of the bovine IgG to detect and present antigen to the foal's immune system 
successfully has not been fully evaluated. 
Most oral equine immunoglobulin products contain relatively low IgG levels and fail to 
increase serum IgG concentrations above 500 mg/dl (Franz et al. 1998; Vivrette et al. 1998). 
Therefore, the objective of this study was to evaluate the adequacy of a concentrated oral 
purified equine serum product containing 36 g of IgG/dose. 
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Materials and Methods 
Animals and collection of samples 
Ten foals of Quarter Horse breeding were alternately assigned to either the treated group or 
the control group. The dams of the foals ranged in age from 4 to 21 years. Treated foals 
were administered 250 ml of an oral serum product at 1 h and 3 h of age via nasogastric 
intubation. These foals were muzzled to prevent nursing from their dam. Supplemental milk 
replacer1 (200 ml/feeding) was provided to the treated foals at 6 h and 9 h of age. Mares with 
treated foals had their udders stripped at 1, 3, 6, and 9 h post parturition. The initial 
colostrum collected (200 ml) was fed back to the treated foals when the muzzle was removed 
at 12 h of age. Control foals were allowed to nurse from their dams ad libitum. Ten ml 
jugular blood samples were collected into tubes using EDTA as the anticoagulant. Samples 
were obtained from all foals (5 treated/5 control) at 1, 3, 5, 7, 9, 10, 11, 12, 24, and 48 h of 
age for determination of concentrations of plasma IgG. 
Oral serum product 
Equine serum was purchased from a closed herd of horses2 and the IgG was concentrated to 
72% purity and verified by radial immunodiffusion3. The purification process involved 
enriching the IgG through standard chemical precipitation, which resulted in the removal of 
albumin. The spray dried product was balanced with 1% dextrose and 0.1M glycine and 
mixed in 250 ml of warm distilled water prior to feeding. Each dose contained 36 g of IgG 
for a total dose of 72 g (2 doses/treated foal x 36 g/dose). 
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Immunoglobulin quantification 
Plasma was harvested from all blood samples by centrifugation and IgG concentrations were 
determined by radial immunodiffusion3. Personnel performing the IgG assay were blinded as 
to the grouping of the foals and the sample collection time. 
Statistical analysis 
Data were analyzed using the analysis of variance (ANOVA) procedure of SAS4 and 
included foal within treatment interaction as the error term. Independent effects included in 
the statistical model were birth weight, dam parity, dam age, and foal sex. Initial IgG level at 
1 h was included as a covariable. Significance was declared as P values less than 0.05. 
Results 
Average foal weight was 50 kg (S.D. ± 6 kg) for control foals and 47 kg (S.D. ± 5 kg) for 
treated foals. Mean values and ranges for plasma IgG concentrations at all sampling periods 
are presented in Table 3.1. Plasma IgG concentrations were higher (p<.05) for treated foals 
compared to control foals at 5 h and 48 h of age. Plasma IgG concentrations were not 
different (p>. 10) at all other time periods measured. All treated foals had plasma IgG 
concentrations in excess of 700 mg/dl by 10 h of age. 
Mean pre-suckling colostrum values at 1 h were 14,466 mg/dl for dams of control foals 
and 11,714 mg/dl for dams of treated foals. There was no difference in colostrum IgG 
concentration between the two groups of foals. 
Discussion 
There are few viable options for producers within the first 24 hours after a foal is born to 
prevent failure of passive transfer if supplemental colostrum is not available. The oral equine 
products currently marketed fail to raise IgG levels to an adequate level, however, there is 
Table 3.1. Mean immunoglobulin G values (mg/dl) and ranges for control and treated foals 
Hours after Birth 
1 3 5 7 9 10 11 12 24 48 
Control 33.0 93.8 308.6* 552.0 697.6 760.2 829.6 815.2 747.8 661.2* 
(±S.D) (73.8) (62.3) (152.4) (264.8) (313.9) (252.3) (266.7) (256.8) (205.1) (198.4) 
Range 0-165 0-159 107-498 217-952 297-1141 464-1143 491-1225 554-1234 590-1099 460-955 
Treated 22.8 139.4 534.0* 802.8 826.0 825.2 844.6 797.4 965.2 943.0* 
(±S.D) (50.9) (50.1) (81.8) (170.1) (178.3) (141.5) (153.8) (153.7) (205.5) (174.8) 
Range 0-114 81-215 457-664 644-1087 661-1029 707-1012 714-1024 597-995 717-1272 753-1213 
* P <  0 . 0 5  
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some evidence that they can provide protection against illness (Franz et al. 1998). 
Intravenous IgG products not only raise foal serum immunoglobulin levels, but also have the 
advantage that they can be administered to a foal of any age. Drawbacks to intravenous IgG 
products include both the invasive nature of administration and the risk of adverse systemic 
reactions. Typical reactions include tachypnea, tachycardia, shaking, depression, diarrhea, 
abdominal discomfort and hyperemic mucous membranes (Liu et al. 1991; Madigan 1997). 
Therefore, oral products provide a safe alternative for foals from mares with a history of 
inferior colostrum quality, foals with a history suggestive of FPT, or simply as a preventative 
measure. 
Two foals from the current study (one control/one treated) had measurable IgG 
concentrations at 1 h even though all births were attended and the foals did not nurse prior to 
the sample. This was not surprising as a small percentage of newborn calves and foals have 
been reported to have minimal IgG levels at birth in other studies (McGuire et al. 1973; 
Edwards et al. 1982). To account for this, IgG concentrations at 1 h were included in the 
statistical model. 
Concentrations of IgG in the control foals were relatively low. It is possible that the 
frequency of sampling interrupted normal foal behavior and resulted in a decrease in suckling 
as one control foal still had an IgG concentration of zero at 3 h. If control foal IgG 
concentrations had been higher, there may have been significant differences between the two 
groups of foals, however, all treated foals still attained IgG levels above 700 mg/dl and two 
foals achieved levels greater than 1000 mg/dl. 
Even though foals from this study were allowed to nurse their dam after 12 h of age, the 
results show that adequate plasma IgG levels can be achieved through the routine oral 
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administration of a concentrated immunoglobulin product within the first 5 hours after birth. 
The increased concentration of IgG observed in the treated foals can be attributed to the high 
concentration of IgG contained in the serum product administered in this study. 
Plasma IgG values were higher at 48 h in treated foals compared to control foals; this can 
be explained by the administration of dam's colostrum after the 12 h sample. It is also 
possible that the equilibrium process was altered in the treated foals by the 12 h colostrum 
feeding. It takes approximately 2-3 d for IgG to reach equilibrium between the intravascular 
and extravascular space and this process may have been delayed in the treated foals by the 12 
h colostrum administration (Reilly and MacDougall, 1973). 
Because this is a newly developed product, further studies are needed to test the efficacy 
of the product for prevention of illness in colostrum deprived foals. The preliminary results 
from this trial support the use of this product for prevention of FPT in newborn foals. 
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CHAPTER FOUR 
CHARACTERIZATION OF A COLOSTRUM REPLACER CONTAINING IgG 
CONCENTRATE AND GROWTH FACTORS 
A paper to be submitted to the Journal of Dairy Science 
C. J. Hammer1, J. D. Quigley2, L. Ribeiro2, and H. D. Tyler3 
ABSTRACT 
The objective of this study was to characterize absorption of colostrum replacer (CR) or 
supplement (CS) containing fractions of bovine plasma. Immunoglobulin concentrate (IGC) 
was prepared from bovine abattoir blood to a final purity of approximately 90% IgG. Bovine 
blood was also processed to produce a fraction containing elevated concentrations of IGF-1 
and TGF-P (GF). Both IGC and GF were spray-dried and blended with other ingredients to 
produce CR (30% IgG) or CS (15% IgG) containing 0 or 5% GF. Holstein bull calves (n = 
40) were removed from the dams immediately after birth and assigned to one of five 
treatments: 1) Pooled colostrum (MC) - 1.9 L of pooled colostrum at 1 and 8 h of age; 2) 
Low supplement (LC) - 1.9 L of CS at 1 and 8 h of age to provide 150 g of IgG; 3) Low 
supplement + GF (LG) - 1.9 L of a CS with GF at 1 and 8 h of age to provide 150 g of IgG; 
4) High supplement (HC) -1.9 L of CR at 1 h of age to provide 150 g of IgG and 1.9 L of a 
commercial milk replacer (MR) at 8 h of age; and 5) High supplement + GF (HG) - 1.9 L of 
a CR with GF at 1 h of age to provide 150 g of IgG and 1.9 L of a commercial MR at 8 h of 
age. Blood was collected by jugular venipuncture at 0 and 24 h for determination of plasma 
IgG. Five calves fed HG, HC, and MC received an oral xylose solution (0.5 g/kg body 
weight) at 2 d of age. Jugular blood samples were obtained at 0 and 2 h after xylose 
1 Graduate student, primary researcher, and author; Iowa State University, Ames, IA. 
2 Research and Development, APC, Inc., Ames, IA 
3 Associate Professor; Iowa State University, Ames, IA. 
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ingestion. Apparent efficiency of IgG absorption (AEA) for IgG was higher (p=.02) for 
calves fed HC and HG compared to those fed LC and LG and was lower (p=.03) for calves 
fed LG and HG compared to those fed LC and HC. IgG concentrations at 24 h were highest 
(pc.0001) in calves fed MC compared to other calves and were higher (p=.048) in calves fed 
HC and HG compared to LC and LG. Calves fed LG and HG had lower (p=.02) IgG 
concentrations at 24 h of age compared to those fed LC and HC. Xylose absorption was not 
influenced by treatment. These results indicate that 150 g of IgG provided in one dose soon 
after birth is superior to 150 g of IgG fed in two doses 7 h apart. Also, addition of a fraction 
of bovine plasma containing elevated concentrations of IGF-1 and TGF-P to the CS and CR 
formulation decreased IgG absorption in the neonatal calf. 
Abbreviation key: AEA = apparent efficiency of IgG absorption, CR = colostrum replacer, 
CS = colostrum supplement, FPT = failure of passive transfer, GF = serum fraction with 
elevated IGF-1 and TGF-p, HC = high supplement; HG = high supplement plus GF; IGC = 
immunoglobulin concentrate, IGF-1 = insulin like growth factor -1, LC = low supplement; 
LG - low supplement plus GF; MC = pooled colostrum; MR = milk replacer; TGF-P = 
transforming growth factor p. 
INTRODUCTION 
Colostrum is vital to the health and survival of the neonatal calf, and 18% of dairy cows 
provide colostrum yields with less than 100 g of IgG, the most commonly recommended 
amount to prevent failure of passive transfer (FPT) (Levieux and Oilier, 1999). Colostrum-
deprived calves are 50-75 times more likely to die before 21 d of age than colostrum-fed 
calves, with most deaths occurring during the first week of life (Smith and Little, 1922; 
Crowley et al., 1994; Wells et al., 1996). Therefore, colostrum supplements (CS) and 
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colostrum replacers (CR) have been developed that can be provided when colostrum is either 
of poor quality or unavailable. Colostrum supplements are preparations intended to provide < 
100 g of IgG/dose and are not formulated to replace colostrum. On the other hand, colostrum 
replacers contain >100 g IgG/dose and usually provide additional nutrients required by the 
calf (Quigley et al., 2002). 
Colostrum not only provides passive immunity for the newborn calf, but it can also have 
profound effects on the development of the neonatal intestine. Villous circumference, area, 
and height and height/crypt depth ratio in the duodenum are higher for calves fed colostrum 
compared to colostrum-deprived calves (Buhler et al., 1998; Blattler et al., 2001). Calves fed 
colostrum also have higher plasma xylose concentrations after administration of xylose 
compared to calves fed milk replacer (MR), suggesting enhanced absorptive capabilities in 
colostrum fed animals (Hammon and Blum, 1997; Kuhne et al., 2000). Rauprich et al. (2000) 
also reported increased xylose uptake in calves fed colostrum compared to calves fed formula 
similar to colostrum but containing 15% of the insulin-like growth factor-1 (IGF-1) content. 
However, Buhler et al. (1998) found no enhancement of gut development in colostrum fed 
calves after oral or subcutaneous injection of IGF-1. Therefore the objective of this study was 
to characterize the absorption of colostrum replacer (CR) or supplement (CS) containing a 
fraction of bovine plasma with elevated concentrations of IGF-1 and transforming growth 
factor-P (TGF-P). 
MATERIALS AND METHODS 
Diet formulation 
Immunoglobulin concentrate (IGC) was prepared from bovine abattoir blood to final 
purity of approximately 90% IgG. The blood was also processed to produce a fraction 
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containing elevated concentrations of IGF-1 and TGF-P (GF). Both IGC and GF were spray-
dried and blended with other ingredients to produce CR (30% IgG) or CS (15% IgG) and 
either containing 0 or 5% GF. Samples of each diet were analyzed for IgG content (Etzel et 
al., 1997) and for proximate nutrients according to AOAC procedures at a commercial 
facility (Silliker Inc., Minnetonka, MN). 
Experimental procedure 
Holstein bull calves (n = 40) were removed from their dams immediately after birth and 
assigned to one of five treatments: 1) Pooled colostrum (MC) -1.9 L of pooled colostrum at 
1 and 8 h of age; 2) Low supplement (LC) -1.9 L of CS at 1 and 8 h of age to provide 150 g 
of IgG; 3) Low supplement + GF (LG) -1.9 L of a CS with GF at 1 and 8 h of age to provide 
150 g of IgG; 4) High supplement (HC) -1.9 L of CR at 1 h of age to provide 150 g of IgG 
and 1.9 L of a commercial milk replacer (MR) at 8 h of age; and 5) High supplement + GF 
(HG) - 1.9 L of a CR with GF at 1 h of age to provide 150 g of IgG and 1.9 L of a 
commercial MR at 8 h of age. Experimental diets were reconstituted in water and mixed in a 
household blender until well blended. The mixture was then poured into a nipple bottle and 
offered to the calf. Amounts not voluntarily consumed were provided via an esophageal 
feeder. 
At 0 and 24 h of age, blood was collected from all calves by jugular venipuncture into 
evacuated tubes containing EDTA. A sample was placed in a microhematocrit tube and 
centrifuged for hematocrit determination. Plasma was collected by centrifugation and total 
protein was determined with a handheld refractometer (Schuco Clinical Refractometer). 
Remaining plasma was frozen (-20°C) for later determination of IgG by turbidimetric 
immunoassay (Etzel et al., 1997). 
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Xylose absorption 
Five calves each from the treatment groups HC, HG, and MC were administered an oral 
xylose solution (0.5 g d-xylose/kg body weight) at 2 d of age approximately 4 h after the 
morning meal. Blood samples were obtained from each calf via jugular venipuncture prior to 
xylose administration and again at 2 h after xylose ingestion. Plasma was collected by 
centrifugation and frozen (-20°C) for later spectrophotometry analysis (Merritt and Duelly, 
1983). 
Statistical analysis 
Experimental data were analyzed using the general linear models procedure of SAS 
(1996). Orthogonal contrasts were used to test differences between MC and CR, low IgG 
dose and high IgG dose, and GF addition. Chi square analysis was used to determine 
differences in FPT. Significance was declared at P < 0.05 unless otherwise noted. 
RESULTS AND DISCUSSION 
The composition of the experimental CS and CR, as well as the MR provided to calves 
on treatment HC and HG, is provided in Table 4.1. The CP% was slightly higher for HC and 
HG diets, however, total protein consumed was similar between treatments since calves on 
treatment HC and HG were fed MR at 8 h of age. The composition of GF is provided in 
Table 4.2. Four calves did not survive until the 24 h blood sample, and were therefore 
excluded from the analysis. Mean BW of calves did not differ among treatments (Table 4.3). 
The frequency of feeding via esophageal feeder also was not different among treatments. 
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Table 4.1. Composition of experimental colostrum supplements, colostrum replacers, and 
milk replacer. 
Item1, % LC LG HC HG MR 
DM 96.8 93.6 95.5 93.6 97.1 
CP 31.3 32.1 40.3 41.5 21.3 
Ash 5.7 5.5 4.8 4.8 7.1 
Fat 19.8 23.6 23.1 218 216 
Items are on a DM basis, except for DM 
2MR = commercial milk replacer provided to calves in treatments HC and HG at 8 h of age 
Table 4.2. Composition of serum fraction GF. 
Item1 Value 
DM, % 96.6 
TP, % 93.24 
Albumin, % 56.64 
IgG, % 19.7 
Ash, % 0.61 
TGF-pi, ng/g 765 
TGF-p2, ng/g 9 
IGF-1, ng/g 1368 
Standard plate count, CFU/g 600 
Endotoxin, EU/g 0.311 
1 Items are on a DM basis, except for DM 
Total IgG intake was 282 g for calves fed MC and 150 g for calves fed all other 
treatments. The GF fraction contributed an additional 4 g of IgG to calves receiving those 
diets. Immunoglobulin G concentrations (Table 4.3) were highest at 24 h of age in calves fed 
MC compared to calves in the other four treatment groups, which is easily attributable to the 
difference in IgG intake. Immunoglobulin G concentrations were higher at 24 h of age in 
calves fed HC and HG compared to LC and LG, even though the total IgG intake was equal 
between all four groups. Apparent efficiency of IgG absorption (AEA) (Table 4.3) was also 
higher for calves fed HC and HG compared to those fed LC and LG. These results contradict 
previous findings that show no difference in serum IgG concentrations and similar AEA after 
feeding calves a large amount at birth or the same amount divided into two or three feedings 
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(Hopkins and Quigley et al., 1997; Morin et al., 1997). However, the observed differences 
may be related to the fact that comparisons in the previous studies were based on feeding 
maternal colostrum, whereas calves in the current study received CS or CR. The AEA for 
colostrum replacers derived from bovine Ig concentrate has been shown to be higher when 
fed once compared to feeding twice after birth 8 h apart (Quigley et al., 2001). The values for 
AEA observed in this trial are similar to those previously reported for CS and CR prepared 
from bovine plasma (Quigley et al., 2002). Immunoglobulin G concentrations were higher in 
calves fed the CS and CR formulations than those previously reported by Quigley et al. 
(1998) for calves receiving 150 g IgG obtained from bovine serum. 
Calves fed LG and HG also had lower IgG concentrations at 24 h of age and lower AEA 
compared to those fed LC and HC, suggesting that addition of GF to the CS and CR 
formulation negatively influenced IgG absorption. Concentrations of TGF-P and IGF-1, 
although concentrated in the serum fraction, were still well below the concentrations found in 
bovine colostrum. Values for IGF-1 and TGF-P 1 in cow colostrum range from 203-1850 
ng/ml and 12.4-42.6 ng/ml, respectively (Hadom et al., 1997; Ginjala and Pakkanen, 1998). 
The fraction of bovine serum may have contained other compounds that either negatively 
affected intestinal absorption or somehow increased IgG metabolism, although at this time it 
is unknown what those compounds may be. 
Preadministration xylose concentrations (Table 4.4) were slightly higher than those 
previously reported. Others have reported preadministration xylose concentrations ranging 
from 7-13 mg/dl in young calves fed colostrum, whole milk, or milk replacer (Seegraber and 
Morrill, 1979; Kuhne et al., 2000). Hammon and Blum (1997) reported even lower 
concentrations of 4-5 mg/dl in calves. Post-administration xylose samples were obtained 2 h 
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after xylose administration and were not different among treatments. Peak xylose values are 
obtained 2-2.5 h after administration of xylose in fasted calves (Seegraber and Morrill, 
1979); however, peak values are reached later in calves fed xylose with the morning meal 
(Kuhne et al., 2000; Rauprich et al., 2000). Previously reported peak xylose values average 
from 42-56 mg/dl over the first 5 weeks of life, and are similar for fasted and non-fasted 
calves (Seegraber and Morrill, 1979; Kuhne et al., 2000). Although the post-administration 
xylose concentrations were higher in this study, the change in xylose concentration was 
similar to previously reported values (Seegraber and Morrill, 1979). 
Table 4.3. Least squares means of treatment parameters for calves fed LC, LG, HC, HG and 
MC. 
Treatment Contrasts 
Item MC LC LG HC HG SE 1 2 3 
No. calves 7 7 7 8 7 
BW, kg 49.37 47.30 45.35 45.18 49.24 1.79 NS3 NS NS 
IgG intake, g 282.2 150 150 150 150 9.4 0.001 NS NS 
Plasma IgG, g/L 
Oh 0 0 0 0 0 0 NS NS NS 
24 h 18.07 10.62 9.14 12.96 10.33 0.86 0.001 0.05 0.02 
Change 0-24 h 18.07 10.62 9.14 12.96 10.33 0.86 0.001 0.05 0.02 
AEA % 29 30 24 35 30 2 NS 0.02 0.03 
FPT4, % 0 42 57 0 28 14 0.06 0.02 NS 
Plasma protein, g/L 
Oh 4.75 4.62 4.37 4.57 4.51 0.15 NS NS NS 
24 h 6.12 5.02 5.20 5.24 4.91 0.17 0.001 NS NS 
Change 0-24 h 1.37 0.40 0.86 0.61 0.40 0.15 0.001 NS NS 
Hematocrit, % 
Oh 40.14 42.57 33.14 37.62 39.28 2.62 NS NS 0.09 
24 h 34.14 35.85 26.66 3185 36.71 1.87 NS 0.04 NS 
Change 0-24 h -6.0 -6.71 -5.50 -2.71 -2.57 1.82 NS 0.07 NS 
MC = 1.9 L of maternal colostrum at 1 and 8 h; LC = 1.9 L of CS at 1 and 8 h; LG = 1.9 L 
of CS with GF at 1 and 8 h; HC = 1.9 L of CR at 1 h and 1.9 L of MR at 8 h; HG = 1.9 L of 
CR with GF at 1 h and MR at 8 h 
^Contrasts: 1 = MC vs. CR; 2 = Low vs. High; 3 = 5% GF vs. 0% GF 
3P>0.10 
^Failure of passive transfer (IgG <10 g/L) 
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Table 4.4. Least squares means for xylose absorption in calves fed HG, HC, and MC. 
Treatment Contrasts 
Item MC HC HG SE 1 2 
No. calves 5 6 5 
Xylose absorption, mg/dl 
Oh 16.56 15.22 15.89 0.56 NS3 NS 
2 h 71.55 55.97 60.76 9.0 NS NS 
Change 0-2 h 54.98 40.74 44.87 8.9 NS NS 
'MC = 1.9 L of maternal colostrum at 1 and 8 h; HC = 1.9 L of CR at 1 h and 1.9 L of MR at 
8 h; HG = 1.9 L of CR with GF at 1 h and MR at 8 h 
^Contrasts: 1 = MC vs. CR; 2 = 5% GF vs. 0% GF 
3P> 0.10 
These results contradict those previously reported that show higher plasma xylose 
concentrations after administration of xylose in colostrum fed calves compared to calves fed 
MR (Hammon and Blum, 1997; Kuhne et al., 2000). However, calves in the current study 
were fed CR at one feeding and MR at the second, compared to the previous trials in which 
calves were fed MR only. Hammon and Blum (1997) observed no difference in xylose 
absorption when calves were fed maternal colostrum at only the first feeding or for more than 
one feeding. The lack of difference in xylose absorption after addition of IGF-1 and TGF-P 
also supports Buhler et al. (1998) who reported no enhancement of gut development after 
oral administration of IGF-1. 
CONCLUSIONS 
Newborn calves readily absorbed the IgG concentrate used in this study, and plasma IgG 
concentrations at 24 h of age were indicative of successful passive transfer. The results from 
this study indicate that 150 g of IgG provided in one dose soon after birth is superior to 150 g 
of IgG fed in two doses 7 h apart. These data also suggest that addition of a fraction of 
bovine plasma containing elevated concentrations of IGF-1 and TGF-P to the CS and CR 
formulation decreased IgG absorption in the neonatal calf. Further studies are needed to 
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determine how growth factors influence intestinal immunoglobulin absorption in the neonatal 
calf. 
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CHAPTER FIVE 
EFFECTS OF DIFFERENT LEVELS OF PASSIVE IMMUNITY ON RESPONSE TO 
INFUSION OF INTRAVENOUS IMMUNOGLOBULIN IN CALVES 
A paper to be submitted to the Journal of Dairy Science 
C. J. Hammer4, J. D. Quigley5, and H. D. Tyler6 
ABSTRACT 
The objective of this study was to determine the effect of different levels of passive 
immunity on calf response to administration of intravenous immunoglobulin (IVIG). The 
IVIG was concentrated from bovine abattoir blood to a final concentration of approximately 
35 g IgG/L. Dairy breed bull calves (n = 32) were removed from their dams immediately 
after birth and assigned to one of four treatment groups. Calves in the high group (H) 
received 2 L of pooled MC at 1 h and 12 h after birth. Calves in the low group (L) received 1 
L of MC mixed with 1 L of milk replacer at 1 h and 12 h after birth. Calves in the deprived 
group (D) received 2 L of milk replacer at 1 h and 12 h after birth. Calves in the control 
group (C) received 2 L of pooled MC at 1 h and 12 h after birth. At 3d of age, calves in the 
H, L, and D group all received 500 ml of IVIG administered via jugular catheter. Calves in 
the control group received 500 ml of 0.9% NaCl. Blood was collected by jugular 
venipuncture prior to infusion, and again at 24 h post infusion for determination of plasma 
IgG by turbidimetric immunoassay. Mean plasma IgG concentrations at 3d of age were 
different between the H, L, and D group of calves, but not between H and C. Mean plasma 
IgG at 3 d of age were 12.1, 6.3, 0.0, and 11.8 g/L for calves in H, L, D, and C, respectively. 
4 Graduate student, primary researcher, and author; Iowa State University, Ames, IA. 
5 Research and Development, APC, Inc., Ames, IA. 
6 Associate Professor; Iowa State University, Ames, IA. 
86 
Calves in all treatment groups had a greater rise in mean plasma IgG compared to C calves at 
24 h post infusion. Mean increase in plasma IgG at 24 h post infusion were 1.8, 2.4, 3.0, and 
-0.1 g/L for calves in H, L, D, and C, respectively. These data indicate that IVIG can 
increase plasma IgG levels in calves regardless of the level of passive immunity present at 
infusion. 
Abbreviation key: FPT = failure of passive transfer, IVIG = intravenous concentrated 
plasma product, MC = maternal colostrum, MR = milk replacer. 
INTRODUCTION 
Calves are essentially agammaglobulinemic at birth, although a small percentage of 
calves may have negligible amounts of circulating serum IgGi, IgG^, IgM, and IgA. In 
ruminants, passive immunity is provided through ingestion of colostrum by the neonate after 
birth (Smith and Holm, 1948; Klaus et al., 1969). Colostrum is vital to the health and survival 
of the neonatal calf, and 18% of dairy cows provide colostrum yields with less than 100 g of 
IgG, the most commonly recommended amount to prevent failure of passive transfer (FPT) 
(Levieux and Oilier, 1999). Colostrum-deprived calves are 50-75 times more likely to die 
before 21 d of age than colostrum-fed calves, with most deaths occurring during the first 
week of life (Smith and Little, 1922; Crowley et al., 1994; Wells et al., 1996). 
Oral colostral supplements and replacers are available and can be offered when either the 
dam's or some other fresh or frozen colostrum source is not available; however, the calf 
small intestine is unable to absorb intact IgG molecules after approximately 26 h of age (Stott 
et al., 1979a). Once the period of intestinal permeability to immunoglobulin molecules has 
passed, passive immunity can be provided by intravenous, intraperitoneal, or subcutaneous 
injection (Anderson et al., 1987; Crowley et al., 1994; Quigley and Welbom, 1996). Calves 
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provided with an intravenous infusion of a bovine plasma product containing 47 g IgG have 
increases in serum IgG of approximately 2.9 g/L (Quigley and Welborn, 1996). 
The effect of initial IgG concentration at the time of intravenous administration of a 
concentrated bovine plasma product on post infusion IgG concentrations has not been 
examined. Therefore, the objective of this study was to determine the effect of different 
levels of passive immunity on calf response to administration of intravenous immunoglobulin 
(IVIG). 
MATERIALS AND METHODS 
Dairy bull calves (n = 32) that weighed between 36 to 50 kg were obtained immediately 
after birth and assigned to one of four treatments. Calves in the high colostrum group (H) and 
the control group (C) received 2 L of pooled colostrum (MC) at 1 h and 12 h after birth. 
Calves in the low colostrum group (L) received 1 L of MC mixed with 1 L of milk replacer 
(MR) at 1 h and 12 h after birth. Finally, colostrum deprived calves (D) received 2 L of MR 
at 1 h and 12 h after birth. Pooled colostrum was collected prior to the start of the study and 
frozen in 2 L aliquots. Colostrum was thawed in warm water prior to feeding calves at 1 h 
and 12 h of age. All feedings were administered to the calf via esophageal feeder. Calves 
were housed indoors in individual pens for the duration of the project and were offered 2 L of 
milk replacer two-times daily starting at 24 h of age. Water was available ad libitum, but no 
calf starter or hay was offered during the trial. 
Calves in groups H, L, and D received 500 ml of a concentrated plasma product (IVIG) 
administered through a jugular catheter at 3 d of age. Control calves were administered 500 
ml of 0.9% NaCl instead of IVIG at 3 d of age. All infusions were administered slowly over 
approximately 20 minutes. The IVIG used in this trial was concentrated from bovine abattoir 
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blood to a final concentration of approximately 35 g IgG/L. Blood was collected from all 
calves by jugular venipuncture just prior to infusion and again at 24 h post infusion for IgG 
determination by turbidimetric immunoassay (Etzel et al., 1997). 
Experimental data were analyzed using the general linear models procedure of SAS 
(1996). Orthogonal contrasts were used to test differences between H and C, IVIG and saline, 
and H and D. Because of the death of one calf prior to 3 d of age, least squares means are 
reported. Significance was declared at P < 0.05 unless otherwise noted. 
RESULTS AND DISCUSSION 
Mean plasma IgG concentrations at 3 days of age (Table 5.1) were different between H, 
L, and D calves, but not between group H and C calves. This was expected since calves in 
group H and C received colostrum containing 48 g/L IgG, while calves in group L received a 
mix of colostrum and MR providing 21 g/L IgG. Calves in group D received MR only. All 
IgG concentrations for calves in group D were below the detection level of the assay (< 1 
g/L) and were assumed to be zero. 
Table 5.1. Least squares means of treatment parameters for calves with different levels of 
passive immunity. 
Treatments Contrasts 
Item H L D c SE 1 2 3 
No. calves 8 8 8 7 
Colostral IgG, g/L 48.2 21.0 0.0 48.2 
Plasma IgG, g/L 
Pre-infusion 12.11 6.25 0.00 11.79 0.71 NS3 0.001 0.001 
Change (post-pre) 1.83 2.39 3.02 -0.08 0.36 0.001 0.001 0.03 
H = 2 L of MC at 1 h and 12 h after birth, IVIG on d 3; L = 1 L of pooled MC mixed with 1 
L of MR at 1 h and 12 h after birth, IVIG on d 3; D = 2 L of MR at 1 h and 12 h after birth, 
IVIG on d 3; C = 2 L of MC at 1 h and 12 h after birth, 0.9% NaCl on d 3 
^Contrasts: 1 = H vs. C; 2 = IVIG vs. 0.9% NaCl; 3 = H vs. D 
3P>0.10 
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Administration of IVIG resulted in a greater increase in mean IgG concentration at 24 h 
post-infusion compared to calves receiving 0.9% NaCl. Calves in groups H, L, and D all had 
post-infusion increases in IgG concentration, while calves in group C showed a slight 
decrease in IgG concentration. 
The increase observed in plasma IgG concentration in calves from group D is slightly 
higher than observed by Anderson et al. (1987) and is likely a reflection of differences in 
total IgG administered. Calves in the current experiment received concentrated bovine 
plasma containing approximately 35 g/L IgG, whereas calves in the trial conducted by 
Anderson et al. (1987) received bovine plasma for which the IgG content was not reported. 
Immunoglobulin G concentration of adult bovine plasma is approximately 11.2 g/L for IgGi 
and 9.2 g/L for IgGz; however, values are even lower during colostrogenesis in the dairy cow 
(Butler, 1986; Guy et al., 1994). Therefore, it is likely that the content of the IgG in the 
infused product used in that experiment was much lower than in the current study. 
Calves in group D had a greater increase in IgG concentration post IVIG infusion 
compared to calves in group H, suggesting that initial IgG concentration can affect calf 
response to IVIG administration. Administration of IVIG increased IgG concentrations from 
12 to 13.8 g/L in H calves and from 0 to 3 g/L in D calves. Immunoglobulin G concentrations 
above 14 g/L are commonly reported in colostrum-fed calves, with values above 20 g/L 
reported for calves allowed to suckle (Stott et al., 1979b; Stott et al., 1979c). Therefore, it is 
unlikely that an upper threshold for IgG was reached in H calves after administration of 
IVIG. It is also possible that high levels of maternal antibody in H calves increased the 
destruction or elimination of infused IgG. Besser et al. (1988) reported that approximately 
1.5% of infused IgG is excreted daily in the feces, and 2.5% is excreted daily in the urine. 
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However, colostral feeding level did not affect excretion of infused IgG in that trial. Our data 
does not appear to support this previous research in that calves with high levels of passive 
immunity appear to have a higher disappearance of infused IgG compared to colostrum 
deprived calves. 
CONCLUSIONS 
The results from this study indicate that intravenous administration of 500 ml of a 35 g 
IgG/L product to calves at 3 d of age can increase plasma IgG concentrations regardless of 
the calf's initial IgG concentration. This can be beneficial in instances when initial IgG 
concentration is not known, and the health status of the calf is questionable. However, the 
increase in plasma IgG concentration after IVIG administration is greater in calves with 
lower initial IgG concentrations. Further research is needed to determine the mechanism 
resulting in high initial IgG concentration affecting calf response to administration of IVIG. 
REFERENCES 
Anderson, K.L., E. Hunt, and S.A. Fleming. 1987. Plasma transfusions in failure of colostral 
immunoglobulin transfer. Bovine Pract. 22:129-130. 
Besser, T.E., T.C. McGuire, C.C. Gay, and L.C. Pritchett. 1988. Transfer of functional 
immunoglobulin G antibody into the gastrointestinal tract accounts for IgG clearance 
in calves. J. Virol. 62:2234-2237. 
Butler, I.E. 1986. Biochemistry and biology of ruminant immunoglobulins. Prog. Vet. 
Microbiol. Immunol. 2:1-53. 
Crowley, M L., L.J. Fisher, and B.D. Owen. 1994. Blood-derived immunoglobulins in milk 
replacer, or by injection, for improved performance of colostrum deprived neonatal 
calves. Anim. Feed Sci. Technol. 47:245-257. 
Etzel, L.R., R.E. Strohbehn, and J.K. McVicker. 1997. Development of an automated 
turbidimetric immunoassay for quantification of bovine serum immunoglobulin G. 
Am. J. Vet. Res. 58:1201-1205. 
91 
Guy, M A., T.B. McFadden, D.C. Cockrell, and T.E. Besser. 1994. Regulation of colostrum 
formation in beef and dairy cows. J. Dairy Sci. 77:3002-3007. 
Klaus, G.G.B., A. Bennett, and E.W. Jones. 1969. A quantitative study of the transfer of 
colostral immunoglobulins to the newborn calf. Immunology. 16:293-299. 
Levieux, D. and A. Oilier. 1999. Bovine immunoglobulin G, P-lactoglobulin, a-lactoglobulin 
and serum albumin in colostrum and milk during the early post partum period. J. 
Dairy Res. 66:421-430. 
Quigley, J.D. and M.G. Welbom. 1996. Influence of injectable immunoglobulin on serum 
immunoglobulin concentrations in calves. J. Dairy Sci. 79:2032-2037. 
SAS/STAT. 1996. SAS Inst., Inc. Cary. NC. 
Smith, E.L. and A. Holm. 1948. The transfer of immunity to the new-born calf from 
colostrum. J. Biol. Chem. 175:349-357. 
Smith, T. and R.B. Little. 1922. The significance of colostrum to the new-born calf. J. Exp. 
Med. 36:181-198. 
Stott, G.H., D.B. Marx, B.E. Menefee, and G.T. Nightengale. 1979a. Colostral 
immunoglobulin transfer in calves I. Period of absorption. J. Dairy Sci. 62:1632-
1638. 
Stott, G.H., D.B. Marx, B.E. Menefee, and G.T. Nightengale. 1979b. Colostral 
immunoglobulin transfer in calves III. Amount of absorption. J. Dairy Sci. 62:1902-
1907. 
Stott, G.H., D.B. Marx, B.E. Menefee, and G.T. Nightengale. 1979c. Colostral 
immunoglobulin transfer in calves IV. Effect of suckling. J. Dairy Sci. 62:1908-1913. 
Wells, S.J., D A. Dargatz, and S.L. Ott. 1996. Factors associated with mortality to 21 days of 
life in dairy heifers in the United States. Prev. Vet. Med. 29:9-19. 
92 
CHAPTER SIX 
CHARACTERIZATION OF REACTIONS TO INTRAVENOUS 
IMMUNOGLOBULIN IN NEONATAL CALVES 
A paper to be submitted to Veterinary Immunology and Immunopathology 
C. J. Hammer7, J. D. Quigley8, J.A. Roth9 and H. D. Tyler3 
Abstract 
Intravenous immunoglobulin (IVIG) products improve passive immunity in neonates. 
Unfortunately, adverse reactions can occur. This study was designed to determine if 
physiological changes occurring after IVIG administration were the result of rapid infusion 
of large molecular weight molecules or from a more complex mechanism resulting in 
histamine release. The IVIG was concentrated from bovine abattoir blood and contained 
approximately 35 g IgG/L. A dextran (75,000 MW) solution was prepared as a high 
molecular weight control that was similar in osmolarity to the IVIG. Holstein bull calves 
(n=15) under 1 wk of age were assigned to one of three treatment groups: control calves 
received 500 ml of 0.9% NaCl; dextran calves received 500 ml of dextran; IgG calves 
received 500 ml of IVIG. Treatments were rapidly administered (less than 5 min) 
intravenously via jugular catheter. Heart rate, respiration rate, and blood pressure were 
measured prior to treatment, and at 1, 3, 5, 10, 15, 20, 25, 30, 45, 60, 75, and 90 min after 
start of infusion. Blood samples were obtained at the same sampling times, centrifuged, and 
the plasma immediately placed on ice for determination of histamine concentration using an 
enzyme immunoassay. Mean respiration rates were higher in calves treated with IVIG 
7 Graduate student, primary researcher, and author; Iowa State University, Ames, IA. 
8 Research and Development, APC, Inc., Ames, IA. 
9 Professor and Associate Professor; respectively, Iowa State University, Ames, IA. 
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compared to calves in the other two groups at all time periods measured. Mean heart rates 
were lower in calves treated with IVIG compared to calves in the other groups through 30 
min. Calves treated with dextran tended to have higher mean heart rates than calves on the 
control treatment from 10 min through 30 min. Mean blood pressure tended to be higher in 
calves treated with IVIG compared to calves on the control treatment at 1 min, however, 
there were no differences between groups at any other time period. Mean histamine 
concentrations were higher in calves treated with IVIG compared to calves on the control 
treatment at 1 min and were higher in calves treated with dextran at 5 min. Histamine 
concentrations were not different between groups at any other time period. These data 
indicate that adverse reactions to IVIG in calves are not mediated by high molecular weight 
molecules or by histamine release. 
Abbreviations: FPT, failure of passive transfer of immunity; IVIG, intravenous 
immunoglobulin; PAF, platelet activating factor 
Introduction 
Calves are essentially agammaglobulinemic at birth, although a small percentage of 
calves may have negligible amounts of circulating serum IgGi, IgGz, IgM, and IgA. In 
ruminants, passive immunity is provided through ingestion of colostrum by the neonate after 
birth (Smith and Holm, 1948; Klaus et al., 1969). Colostrum is vital to the health and survival 
of the neonatal calf, and 18% of dairy cows provide colostrum yields with less than 100 g of 
IgG, the most commonly recommended amount to prevent failure of passive transfer (FPT) 
(Levieux and Oilier, 1999). Colostrum-deprived calves are 50-75 times more likely to die 
before 21 d of age than colostrum-fed calves, with most deaths occurring during the first 
week of life (Smith and Little, 1922; Crowley et al., 1994; Wells et al., 1996). 
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Oral colostral supplements and replacers are available and can be offered when either the 
dam's or some other fresh or frozen colostrum source is not available; however, the calf 
small intestine is unable to absorb intact IgG molecules after approximately 26 h of age (Stott 
et al., 1979). Once the period of intestinal permeability to immunoglobulin molecules has 
passed, passive immunity can be provided by i.v., i.p., or s.c. injection (Anderson et al., 
1987; Crowley et al., 1994; Quigley and Welborn, 1996). Intravenous infusions of a bovine 
plasma product in calves can increase serum IgG approximately 2.9 g/L (Quigley and 
Welborn, 1996). 
Unfortunately, adverse reactions to intravenous immunoglobulin (IVIG) administration 
can occur and have been reported to occur in approximately 25-55% of foals, a species where 
IVIG products are commonly used to treat FPT (Brown et al., 1991; Liu et al., 1991; Franz et 
al., 1998; McClure et al., 2001). The incidence rate for reactions in foals appears to be related 
to product IgG concentration and method of production, with infusion of lyophilized IgG 
products resulting in an increased rate of reactions (Franz et al., 1998). Intravenous 
immunoglobulin products are also commonly used in human medicine to treat a variety of 
disorders, and adverse reactions are reported to be due to anaphylaxis, complement 
activation, vasoactive properties of the infusion product, or other unknown mechanisms 
(Ewalenko and Deloof, 1984; Stangel et al., 1997). 
Clinical signs of adverse reactions and mechanism of action causing these reactions have 
not been documented in calves receiving IVIG. Therefore, this study was designed to 
characterize adverse reactions to IVIG in calves, and to determine if physiological changes 
occurring after IVIG administration were the result of rapid infusion of large molecular 
weight molecules or were due to a more complex mechanism resulting in histamine release. 
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Materials and methods 
Animals and treatments 
Fifteen Holstein bull calves under one week of age were assigned to one of three 
treatment groups. Treatment groups were: (1) Control, calves received 500 ml of 0.9% NaCl; 
(2) Dextran, calves received 500 ml of a dextran solution; and (3) IgG, calves received 500 
ml of an IVIG product. The dextran solution was prepared by adding 10 g of dextran powder 
(75,000 MW) to 500 ml of a NaCl solution. The dextran solution was prepared so that the 
osmolarity of the solution (269 mOsm) was similar to that of the concentrated plasma 
product (277 mOsm). The IVIG product was prepared from plasma obtained after a two-time 
enrichment process of bovine abattoir blood, with the final product containing approximately 
35 g IgG/L. Previous analysis showed that the IVIG product had low endotoxin levels and 
low complement activity. 
Preparation and sample collection 
Catheters were aseptically placed in each jugular vein so that the treatment could be 
administered through one catheter, while blood samples were simultaneously obtained from 
the other catheter. A catheter was also placed in an ear artery and connected to a manometer 
for arterial blood pressure monitoring. 
Calf heart rate, respiration rate, and mean arterial blood pressure were measured prior to 
the start of treatment infusion, and then at 1,3, 5, 10, 15, 20, 25, 30, 45, 60, 75, and 90 min 
after the start of the infusion. Blood samples were collected into tubes containing EDTA at 
the same sampling times, centrifuged, and the plasma immediately placed on ice for 
determination of histamine concentration. 
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Histamine assay 
The amount of histamine present in plasma was determined using a commercially 
available ELIS A (Immunotech, Marseille, Cedex 9, France). 
Statistical analysis 
Experimental data were analyzed using the general linear models procedure of SAS (SAS 
Inst. Inc., Cary, NC). Multiple measurements recorded over time were analyzed using the 
mixed procedure of SAS with calf within treatment interaction used as the random statement. 
Significance was declared at P < 0.05 and trends towards significance between P > 0.05 and 
f <0.10. 
Results 
Two calves died within 30 minutes after the infusion of IVIG, therefore, they were 
excluded from the results, and least squares means are reported. There was an overall 
treatment effect (P < 0.001), an overall time effect (P < 0.001), and a time by treatment effect 
(P < 0.001) for respiration rate (Figure 6.1). Mean respiration rates were not different among 
treatments prior to the start of infusions, but were higher in IgG calves compared to calves in 
the other two groups at all other time periods measured. Respiration rate also showed a large 
increase after the start of the infusion in calves receiving IVIG, whereas respiration rate 
remained more or less constant in calves on the other two treatments. 
There was no overall treatment effect for heart rate (Figure 6.2); however, there was a 
time effect (P < 0.001) and a time by treatment effect (P < 0.001). Mean heart rates were not 
different among treatments prior to the start of the infusions; however, heart rates decreased 
in calves receiving IVIG, and were lower compared to calves in the other two groups through 
30 min post infusion. Heart rates increased in both control and dextran calves, and dextran 
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calves tended to have higher mean heart rates compared to control calves from 10 min 
through 30 min post infusion. 
Figure 6.1. Mean respiration rates for calves receiving saline, dextran, or intravenous 
immunoglobulin. 
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Figure 6.2. Mean heart rates for calves receiving saline, dextran, or intravenous 
immunoglobulin. 
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There was no overall treatment effect for mean arterial blood pressure (Figure 6.3), 
however there was a time effect (P < 0.001) and there tended to be a time by treatment effect 
(P < 0.07). Mean arterial blood pressure tended to be higher in claves treated with IVIG 
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compared to the other two treatments at 1 min post infusion; however, mean arterial blood 
pressure was not different between treatment groups at any other time period measured. After 
the start of the infusion, blood pressure increased initially and then decreased rapidly in IgG 
calves. In contrast, calves receiving the other two treatments had a more gradual increase and 
subsequent decrease in arterial blood pressure. 
Figure 6.3. Mean arterial blood pressure for calves receiving saline, dextran, or intravenous 
immunoglobulin. 
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Mean histamine concentrations (Figure 6.4) were higher in calves treated with IVIG 
compared to calves in the control treatment at 1 min and were higher in calves treated with 
dextran at 5 min. Histamine concentrations were not different between treatment groups at 
any other time period measured. 
Discussion 
The IVIG product utilized in this trial consistently caused obvious clinical signs of 
infusion reactions in all calves. Within seconds after the start of the infusion, calves showed 
increases in respiration rate and became increasingly dull and lethargic. In contrast, calves 
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receiving the dextran and saline solutions showed no visible clinical signs of discomfort, 
although they did show increases in heart rate. The increase in heart rate is likely due to 
expansion in fluid volume, and could be attributed to the rapid infusion of large molecular 
weight molecules in the dextran group. 
Figure 6.4. Mean histamine concentration for calves receiving saline, dextran, or intravenous 
immunoglobulin. 
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There are three ways by which exposure to a substance can cause anaphylaxis: 1. 
exposure to a foreign protein that results in IgE antibody formation. Reexposure results in 
IgE mediated degranulation of mast cells and basophils; 2. formation of immune complexes 
that activate the complement cascade; and 3. administration of certain agents (hyperosmolar 
solutions, radiocontrast agents, etc.) that directly stimulate the release of mediators by 
unknown mechanisms (Bochner and Lichtenstein, 1991). Classic anaphylactic reactions are 
defined as resulting from a Type I immune response, also called immediate hypersensitivity. 
This type of reaction requires three components: 1. an antigen; 2. IgE antibody; and 3. 
effector cells such as mast cells and basophils that synthesize and release pharmacologic 
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mediators (Ewalenko and Deloof, 1984; Carlson et al., 1986). Reactions that appear clinically 
similar to anaphylactic reactions, but are not mediated by IgE are referred to as anaphylactoid 
reactions (Ewalenko and Deloof, 1984; Carlson et al., 1986). Because the calves on this trial 
did not have previous exposure to IVIG, it is unlikely that IgE mediated the observed 
reactions. Therefore, the observed reactions in this trial will be classified as anaphylactoid 
reactions for the remainder of this discussion. 
Increased histamine concentrations are often observed in anaphylactic and anaphylactoid 
reactions. However, some studies report increased histamine levels after challenge in control 
mice (Choi et al., 1998), while others report no change in histamine levels before or after 
anaphylaxis in both control and mast cell deficient mice (Jacoby et al., 1984). Hypotension 
and death due to anaphylactic reactions in mice also do not appear to require mast cell-
derived mediators (Martin et al., 1993; Miyajima et al., 1997). Adverse reactions to IVIG in 
humans have also been shown to be associated with increases in IL-6 and thromboxane B% 
without concurrent changes in blood pressure, kininogen, histamine, or tryptase (Bagdasarian 
et al., 1998). 
All histamine concentrations reported in this study were assumed to be well within the 
normal range. Plasma histamine concentrations were never greater than 3 nM histamine. 
Emau et al. (1984) reported resting plasma histamine concentrations of 12 nM in six-month-
old calves, and normal plasma histamine concentrations in humans range from 2-8 nM 
(Morel and Delaage, 1988). Mean whole blood values for histamine in calves at 1 week of 
age are 173 nM (Wrenn et al., 1963), and whole blood histamine concentrations are generally 
over 100 times greater than plasma histamine concentrations (Morel and Delaage, 1988). 
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Because no elevation in histamine was observed in the calves showing severe 
anaphylactoid reactions, it is likely that the reactions were caused by the release of another 
mediator such as platelet activating factor (PAP). Incubation with IVIG causes activation of 
neutrophils and macrophages via Fc receptors resulting in PAF release (Bleeker et al., 1989; 
Teeling et al., 1998; Bleeker et al., 2000). Rabbits have been shown to release increased 
amounts of PAF into their plasma within 120 sec after antigen challenge during IgE-induced 
systemic anaphylaxis (Pinckard et al., 1979). Anaphylactic shock in mast cell deficient mice 
is suppressed by CV-3988, a specific antagonist to PAF, but not by cyproheptadine, an 
antagonist to histamine and serotonin (Arimura et al., 1990). Pretreatment with PAF 
acetylhydrolase or PAF antagonist also blocks fatal anaphylactic reactions in both mast cell 
deficient and control mice (Choi et al., 1998; Fukuda et al., 2000). 
The systemic responses and mortality associated with anaphylaxis are mediated through 
FcRy, as mice lacking the FcRy show no cardiopulmonary changes or mast cell 
degranulation, and do not die after induction of anaphylaxis. A functional FcsRI is not 
required for mast cell degranulation or mortality associated with anaphylaxis, as mice lacking 
this receptor exhibit responses similar to FcsRI +/+ mice (Miyajima et al., 1997). The 
production of PAF is unrelated to mast cell activation and depends on mononuclear cell 
activation via FceRII or FcRy (Pellon et al., 1993). 
Administration of contrast media and hyperosmolar solutions to humans can also cause 
reactions similar to those observed from infusion of IVIG (Genovese et al., 1996). However, 
the osmolality of the dextran and the IVIG solution were both similar to the osmotic pressure 
in calves. The osmotic pressure in newborn calves is 293 mOsm/L and decreases to 286 
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mOsm/L after feeding (McEwan et al., 1968). Thus, hyperosmolarity is not the cause of the 
anaphylactoid reactions observed in these calves. 
These data indicate that the adverse reactions to IVIG observed in this trial are not 
mediated either by high molecular weight molecules or by the release of histamine. Further 
research is needed to determine the role of platelet activating factor and other potential 
mechanisms in anaphylactoid reactions in calves. 
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CHAPTER SEVEN 
GENERAL CONCLUSIONS 
The research presented in this dissertation represents a continuing effort to understand 
colostral supplements and replacers that provide exogenous passive immunity to neonatal 
animals. The newborn calf and foal are at an increased risk for disease and death if adequate 
levels of passive immunity are not attained (Boyd, 1972; McGuire et al., 1977; Clabough et 
al., 1991; Wittum and Perino, 1995). Complicating the ability of the neonate to attain 
adequate passive immunity levels is the fact that the small intestine of the calf and foal is 
only able to absorb intact immunoglobulins for approximately 24 h after birth (Jeffcott, 1974; 
Stott et al., 1979). Exogenous supplements to enhance passive immunity can be given orally 
provided the neonate is less than 24 h old, or by intravenous injection after that time. The 
findings from the studies described in this dissertation support the fact that passive immunity 
can be enhanced through both of these methods. 
In the study described in Chapter Two, foals were offered a colostrum supplement at 10 
and 12 h of age to provide a total of 24 - 30 g of IgG. All foals were allowed to nurse their 
dams, and the supplement was tested for its ability to enhance passive immunity in naturally 
nursing foals. This study showed that providing a colostrum supplement with low IgG 
concentration does not raise circulating IgG concentrations in naturally suckling foals. 
In Chapter Three, a more concentrated oral product for foals was studied that provided a 
total of 72 g of IgG. In this study, supplement treated foals were muzzled to prevent nursing 
from their dam through 12 h of age. Treated foals had higher IgG concentrations compared to 
control foals at 5 h and 48 h of age, and IgG concentrations were not different between the 
two groups at any other time period measured. This study showed that providing foals with a 
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colostrum supplement high in IgG soon after birth could result in circulating IgG 
concentrations similar to or better than that of foals allowed to suckle. 
Chapter Four described a study looking at providing newborn calves with colostrum 
supplements or replacers designed to provide a total of 150 g of IgG. A second concentrated 
plasma fraction that contained elevated concentrations of IGF-1 and TGF-P was also added 
to two of the treatment groups. Feeding 150 g of IgG at 1 h of age was superior to feeding 
150 g of IgG split in two doses 7 h apart. All calves that received 150 g of IgG in one dose 
soon after birth had plasma IgG concentrations above the recommended concentration of 10 
g/L. However, addition of a plasma fraction containing elevated growth factors decreased 
plasma IgG concentration. Although the growth factors were concentrated in the serum 
fraction, concentrations were still well below those found in bovine colostrum (Hadom et al., 
1997; Ginjala and Pakkanen, 1998). It is not possible to determine the exact mechanism 
responsible for the decrease in plasma IgG, but it can be concluded that elevated levels of 
growth factors in supplement formulations used in this trial either decreased IgG absorption 
from the small intestine or increased IgG metabolism. 
Although the three trials looking at oral passive immunity products cannot be compared 
directly, several conclusions can be made. First, products containing low levels of IgG are 
ineffective for increasing plasma IgG concentrations in neonates that are provided with 
colostrum. Concentrated IgG products providing 72 g of IgG for foals and 150 g of IgG for 
calves are effective in raising plasma IgG concentrations above the recommended level 
needed to prevent failure of passive transfer in these animals. Second, addition of elevated 
concentrations of IGF-1 and TGF-P to colostrum replacer formulations does not enhance IgG 
absorption, and in fact appears to either inhibit IgG absorption or increase IgG metabolism. 
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The final two studies described in this dissertation examined the intravenous use of 
concentrated bovine plasma (IVIG). Chapter Five was designed to examine the effects of 
initial IgG concentration on calf response to IVIG. Initial IgG concentration appears to 
influence calf response to IVIG in that calves with lower initial plasma IgG concentrations 
have a larger increase in plasma IgG concentration after IVIG infusion. The design of this 
study did not allow determination of the mechanism responsible for this change. 
Radiolabeling of the infused IgG molecules would allow half-life of the IVIG to be 
calculated and excretion rate for the IVIG could be determined. 
Unfortunately, some calves exhibit adverse reactions during the infusion of IVIG. 
Chapter Six was designed to characterize these reactions as they occur, and to also determine 
if the reactions were related to the rapid infusion of large molecular weight molecules. The 
incidence rate of adverse reactions to IVIG in humans is often associated with rapid infusion 
rate (Stangel et al., 1997). Because we wanted to provide the greatest risk for inducing 
adverse reactions in the calves, all treatments were administered in less than 5 min through a 
large bore jugular catheter. All calves that received IVIG showed classic signs of infusion 
reactions including tachypnea and bradycardia, and two calves died within 30 min of the start 
of the infusion. 
Classic anaphylactic reactions are defined as resulting from a Type I immune response 
and require three components: 1) an antigen; 2) IgE antibody; and 3) effector cells such as 
mast cells and basophils that synthesize and release pharmacologic mediators (Carlson et al., 
1986). Reactions that appear clinically similar to anaphylactic reactions, but are not mediated 
by IgE are referred to as anaphylactoid reactions (Carlson et al., 1986). The clinical signs of 
adverse reactions resulting from IVIG infusion in humans are usually associated with the 
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release of preformed mediators from mast cells and basophils, including the release of 
histamine (Bochner and Lichtenstein, 1991). Because the calves in this trial would not be 
expected to have circulating IgE antibodies against the IVIG, we classified the reactions 
observed in the trial as anaphylactoid. However, because the reactions observed in these 
calves appeared similar to anaphylactic reactions, elevated histamine concentrations were 
expected. Surprisingly, there were no differences between treatment groups for mean arterial 
blood pressure or for plasma histamine concentration. In support of our finding, Bagdasarian 
et al. (1998) reported adverse reactions to IVIG in humans associated with increases in IL-6 
and thromboxane B2, but without concurrent changes in blood pressure, kininogen, 
histamine, or tryptase. Unfortunately, the design of the experiment described in Chapter Six 
did not allow us to answer which mechanism, other than histamine release, accounted for the 
adverse clinical signs observed in the IVIG calves. 
Potent inflammatory mediators resulting from arachidonic acid metabolism, such as 
platelet activating factor (PAF), prostaglandin E2, thromboxane B2, and leukotriene C4 may 
be involved in the anaphylactoid reactions to IVIG observed in calves. The release of PAF in 
mast cell deficient mice leads to clinical signs of anaphylaxis (Arimura et al., 1990). Also, 
anaphylactic shock in mice is suppressed by PAF acetylhydrolase or PAF antagonists, but not 
by cyproheptadine, an antagonist to histamine and serotonin (Arimura et al., 1990; Choi et 
al., 1998; Fukuda et al., 2000). It is clear that if IVIG products are to be made available 
commercially, further research must be completed in order to eliminate the risk for adverse 
reactions, or at the very least, minimize their detrimental effects. 
In summary, colostrum is vital to the health of the neonate. If colostrum is not available, 
and the neonate is less than 24 h old, a colostrum replacer providing at least 72 g of IgG for 
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foals or 150 g of IgG for calves should be provided. When neonates are older than 24 h of 
age, IVIG can be provided. The increase in circulating IgG concentrations after IVIG 
administration is small, and therefore multiple doses may be required to raise IgG 
concentrations to a protective level. 
There is a vast amount of knowledge still awaiting discovery in the field of exogenous 
passive immunity. The half-life of passively administered IgG has yet to be determined. The 
effects of different manufacturing methods on IgG absorption have been lightly examined, 
although new and improved methods are always evolving. A more challenging research area 
deals with optimal IgG concentrations needed to confer disease protection. How does this 
differ for different pathogens? How does this change with management conditions? Passive 
immunity is of the utmost importance to neonatal animals until they reach an age where 
endogenous immunity can adequately protect against disease. Any research that increases our 
ability to enhance passive immunity will improve health and survivability of the neonates 
during this vulnerable time. 
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APPENDIX 
COMPLEMENT FIXATION TESTING OF AN INTRAVENOUS 
IMMUNOGLOBULIN PRODUCT 
Objective 
The objective of this experiment was to test the intravenous immunoglobulin product 
used in Chapter Five and Six for complement activation activity. 
Materials and Methods 
Sheep whole blood was collected via jugular venipuncture into sterile tubes containing 
EDTA. The blood was mixed with an equal portion of Alsever's solution and refrigerated 
until needed. Erythrocyte suspensions were prepared as needed after centrifugation and 
resuspension in phosphate buffered saline (PBS). Anti-sheep red blood cell (hemolysin) and 
guinea pig complement were used to determine complement fixation (Colorado Serum 
Company, Denver, CO). Hank's Balanced Salt Solution (with Ca++ and Mg++) was utilized 
as the diluent. Blood was also collected from three cows and the serum pooled for use as a 
complement source in Experiment 1. 
EXPERIMENT 1 
Experimental Design 
Experiment 1 was designed to determine the optimal dilution of hemolysin and 
complement required to run the assay. All dilutions were run in triplicate, and the microliter 
plate was prepared as diagrammed in Table A.l. The same experimental design was also 
repeated using bovine serum in place of guinea pig complement as the complement source. 
Results 
The results for guinea pig complement are presented in Table A.2. 
Table A.l. Microliter plate set up for complement fixation Experiment 1 
Complement Hemolysin 
1:1000 1:2000 1:4000 1:8000 1:16000 1:32000 1:64000 None 
1:5 25 /il H1 
25 /il RBC2 
50 fil D3 
25 fil C4 
25 /JLI H 
25 /il RBC 
50 filD 
25 filC 
25 fil H 
25 fil RBC 
50 fil D 
25 fil C 
25 /il H 
25 fil RBC 
50 /il D 
25 /il C 
25 /il H 
25 fil RBC 
50 /il D 
25 /il C 
25 /il H 
25 /il RBC 
50 fil D 
25 /il C 
25 /il H 
25 /il RBC 
50 fil D 
25 /il C 
0 /il H 
25 fil RBC 
75 fil D 
25 filC 
1:10 25 fil H 
25 fil RBC 
50 ni D 
25 filC 
25 fil H 
25 fil RBC 
50 fil D 
25 filC 
25 fil H 
25 fil RBC 
50 fil D 
25 fil C 
25 /il H 
25 fil RBC 
50 /il D 
25 /ilC 
25 /il H 
25 fil RBC 
50 fil D 
25 filC 
25 /il H 
25 /il RBC 
50 fil D 
25 filC 
25 /il H 
25 /il RBC 
50 fil D 
25 filC 
0 /il H 
25 fil RBC 
75 /il D 
25 (ilC 
1:20 25 /il H 
25 /il RBC 
50 ill D 
25 filC 
25 fil H 
25 fil RBC 
50 fil D 
25 fil C 
25 /il H 
25 /il RBC 
50 fil D 
25 fil C 
25 /il H 
25 /il RBC 
50 /il D 
25 /ilC 
25 /il H 
25 /il RBC 
50 fil D 
25 filC 
25 /il H 
25 /il RBC 
50 /il D 
25 /ilC 
25 /il H 
25 /il RBC 
50 /il D 
25 filC 
0 /il H 
25 /il RBC 
75 /il D 
25 filC 
1:40 25 ill H 
25 ill RBC 
50 ill D 
25 filC 
25 fil H 
25 fil RBC 
50 /il D 
25 fil C 
25 /il H 
25 /il RBC 
50/ilD 
25 filC 
25/il H 
25 /il RBC 
50 /il D 
25 /ilC 
25 /il H 
25 fil RBC 
50 fil D 
25 filC 
25/il H 
25 fil RBC 
50 fil D 
25 filC 
25 /il H 
25 fil RBC 
50 /il D 
25 filC 
0 /il H 
25 /il RBC 
75 fil D 
25 /ilC 
1:80 25 fil H 
25 fil RBC 
50 ixl D 
25 jilC 
25 fil H 
25 fil RBC 
50 fil D 
25 filC 
25 /il H 
25 /il RBC 
50 fil D 
25 filC 
25 ill H 
25 fil RBC 
50 /il D 
25 /ilC 
25 fil H 
25 fil RBC 
50 fil D 
25 /il C 
25 /il H 
25 fil RBC 
50 fil D 
25 /ilC 
25 /il H 
25 fil RBC 
50 fil D 
25 /ilC 
0 /il H 
25 /il RBC 
75 /il D 
25 /il C 
1:160 25 /il H 
25 /il RBC 
50 fil D 
25 filC 
25 fil H 
25 fil RBC 
50 fil D 
25 fil C 
25 fil H 
25 fil RBC 
50/ilD 
25 filC 
25 /il H 
25 fil RBC 
50 /il D 
25 filC 
25 fil H 
25 fil RBC 
50 fil D 
25 fil C 
25 fil H 
25 fil RBC 
50 fil D 
25 filC 
25/il H 
25 fil RBC 
50 /il D 
25 /ilC 
0 /il H 
25 /il RBC 
75 /il D 
25 /ilC 
1:320 25 /il H 
25 fil RBC 
50 filD 
25 nic 
25 fil H 
25 fil RBC 
50 fil D 
25 fil C 
25 fil H 
25 fil RBC 
50 fil D 
25 /il C 
25 /il H 
25 fil RBC 
50 fil D 
25 /il C 
25/il H 
25 fil RBC 
50 fil D 
25 /il C 
25 /il H 
25 fil RBC 
50 fil D 
25 /il C 
25 fil H 
25 fil RBC 
50 fil D 
25 /ilC 
0 /il H 
25 /il RBC 
75 /il D 
25 filC 
None As above 
except for 25 
/il D in place 
of C 
As above 
except for 25 
fil D in place 
of C 
As above 
except for 25 
fil D in place 
of C 
As above 
except for 25 
fil D in place 
of C 
As above 
except for 25 
/il D in place of 
C 
As above 
except for 25 
fil D in place of 
C 
As above 
except for 25 
fil D in place of 
C 
As above 
except for 25 
/il D in place 
of C 
H = hemolysin in 1:4000 dilution 
RBC = 0.5% sheep red blood cell suspension 
3D = diluent 
4C = guinea pig complement 
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Table A.2. Complement fixation results for Experiment 1 
Complement Hemolysin 
1:1000 1:2000 1:4000 1:8000 1:16000 1:32000 1:64000 None 
1:5 Lysis Lysis Lysis Lysis Lysis Lysis Partial 
lysis 
Partial 
lysis 
1:10 Lysis Lysis Lysis Lysis Partial 
lysis 
Pellet Pellet Pellet 
1:20 Lysis Lysis Lysis Partial 
lysis 
Partial 
lysis 
Pellet Pellet Pellet 
1:40 Lysis Lysis Partial 
lysis 
Partial 
lysis 
Pellet Pellet Pellet Pellet 
1:80 Lysis Partial 
lysis 
Partial 
lysis 
Pellet Pellet Pellet Pellet Pellet 
1:160 Partial 
lysis 
Partial 
lysis 
Pellet Pellet Pellet Pellet Pellet Pellet 
1:320 Partial 
lysis 
Pellet Pellet Pellet Pellet Pellet Pellet Pellet 
None Partial 
lysis 
Partial 
lysis 
Partial 
lysis 
Partial 
lysis 
Partial 
lysis 
Partial 
lysis 
Partial 
lysis 
Partial 
lysis 
No complete lysis was observed when bovine serum was used as the complement source. 
Conclusions 
Dilutions of 1:20 guinea pig complement and 1:4000 hemolysin are the optimal dilutions 
to use in this test system. Bovine serum does not work as a complement source at the 
dilutions tested. 
EXPERIMENT 2 
Experimental Design 
Experiment 2 was designed to test the complement fixation ability of an intravenous 
immunoglobulin product (IVIG). The IVIG was also tested as a 1:1 dilution as the cloudiness 
of the product made visualization of results difficult. All dilutions were run in triplicate, and 
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the microti ter plate was prepared as diagrammed below in table A.3. All columns below the 
1:40 complement dilution were filled as described for the 1:40 complement dilution. 
Table A.3. Microtiter plate set up for complement fixation Experiment 2 
Complement 
Dilution 
Well N umber 
1-3 4-6 7-9 10-12 
1:40 25 fil H1 
25 fil RBC2 
50 fil D3 
25 fil C4 
OjulH 
25 fil RBC 
75 /il D 
25 filC 
25 fil H 
25 fil RBC 
25 fil D 
25 ill C 
25 fil IVIG5 
25 fil H 
25 fil RBC 
25 fil D 
25 /tlC 
25 fil dilute 
IVIG6 
1:80 25 pel H 
25 fil RBC 
50 filD 
25 julC 
0 fil H 
25 ni RBC 
75 ill D 
25 (ilC 
25 (il H 
25 fil RBC 
25 ill D 
25 filC 
25 jul IVIG5 
25 /il H 
25 /il RBC 
25 fil D 
25 /ilC 
25 ill dilute IVIG 
1:160 25 ill H 
25 fil RBC 
50 fil D 
25 /ilC 
Oju lH 
25 ill RBC 
75 nlD 
25 ill C 
25 ill H 
25 fil RBC 
25 /zlD 
25 /tlC 
25 nl IVIG5 
25 ill H 
25 fil RBC 
25 fil D 
25 filC 
25 ill dilute IVIG 
1:320 25 fil H 
25 [il RBC 
50 /ilD 
25 filC 
0 /dH 
25 ill RBC 
75  /dD 
25 /ilC 
25 fil H 
25 ill RBC 
25 ill D 
25 filC 
25 fil IVIG5 
25 ill H 
25 fil RBC 
25  ju lD 
25 filC 
25 fil dilute IVIG 
None As above except 
for 25 fil D in 
place of C 
As above except 
for 25 /il D in 
place of C 
As above except 
for 25 /il D in 
place of C 
As above except 
for 25 fil D in 
place of C 
2RBC = 0.5% sheep red blood cell suspension 
3D = diluent 
4C = guinea pig complement 
5IVIG = intravenous immunoglobulin product 
^Dilute IVIG =1:1 dilution of IVIG with heat inactivated bovine serum 
Results 
The results are presented in Table A.4. 
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Conclusions 
The addition of IVIG in the test system did not affect complement at a hemolysin dilution 
of 1:4000. 
Table A.4. Complement fixation results for Experiment 2 after centrifugation (1 min x 200g) 
Complement 
Dilution 
Well IN umber 
1-3 4-6 7-9 10-12 
1:40 Lysis Pellet Lysis Lysis 
1:80 Partial lysis Pellet Partial lysis Lysis 
1:160 Pellet Pellet Partial lysis Partial lysis 
1:320 Pellet Pellet Pellet Partial lysis 
None Pellet Pellet Pellet Pellet 
